anastrozole and tamoxifen

anastrozole has been researched along with tamoxifen in 554 studies

Research

Studies (554)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's17 (3.07)18.2507
2000's324 (58.48)29.6817
2010's177 (31.95)24.3611
2020's36 (6.50)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Bellavance, E; Luu-The, V; Poirier, D1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Bharate, SS; Vishwakarma, RA1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM1
Buzdar, AU; Hortobagyi, GN; Plourde, PV1
Hannaford, M1
Cala, KM; Landrum, DP; Mahendroo, MS; Russell, DW1
Buzdar, AU; Roseman, BJ; Singletary, SE1
Blamey, RW; Cheung, KL; Ellis, IO; Elston, CW; Nicholson, RI; Pinder, SE; Robertson, JF; Willsher, PC1
Buzdar, AU9
Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W1
Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, J; Yue, W1
Baum, M; Blackman, GM; Dowsett, M; Howell, A; King, N; Ponzone, R; Tobias, JS; von Euler, M; Welch, H1
Hamilton, A; Piccart, M1
Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK1
Brodie, A; Gimbel, M; Grigoryev, D; Liu, Y; Long, BJ; Lu, Q1
Bland, KI; Buzdar, AU1
Bland, KI1
Bellamy, C; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Renshaw, L1
Harvey, HA; Santen, RJ1
Fujiwara, K; Hohjoh, T; Ikeda, T; Kawaguchi, M; Kitajima, M; Masamura, S; Matsui, A; Mitsui, Y; Takayama, S; Tokura, H1
Bonneterre, J; Koralewski, L; Krzakowski, M; Mauriac, L; Robertson, J; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A1
Bonneterre, J; Koralewski, P; Krzakowski, M; Mauriac, L; Robertson, JF; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A1
Burton, G; Buzdar, A; Harwin, W; Mangalik, A; Nabholtz, JM; Pollak, M; Steinberg, M; von Euler, M; Webster, A1
Sonoo, H; Watanabe, T1
Baum, M; Thornton, H; Tobias, JS1
Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA1
Mokbel, K2
Panasci, LC1
Bagley, CM; Rowbotham, RK1
Bolton, M; Copur, MS; Ledakis, P; Muhvic, J; Norvell, M1
Tonkin, K1
Costa, SD; Kaufmann, M1
Bergmann, L1
Tominaga, T1
Cuzick, J; Dowsett, M; Howell, A; Jackson, I1
Lønning, PE2
Burstein, HJ; Winer, EP1
Murray, R1
Boeddinghaus, I; Dixon, M; Dowsett, M; Ebbs, S; Gui, G; Harper-Wynne, C; Hills, M; Sacks, N; Salter, J; Smith, I1
Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Sahmoud, T; Steinberg, M; Thürlimann, B; von Euler, M; Webster, A1
Nabholtz, JM; Reese, DM1
Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR1
Sledge, GW1
Baum, M4
Goss, PE1
Nicholls, H1
Jones, SE1
Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R1
Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G1
Ravdin, P1
Baum, M; Budzar, AU; Cuzick, J; Forbes, J; Houghton, JH; Klijn, JG; Sahmoud, T1
Ingle, JN5
Köberle, D; Thürlimann, B2
Cummings, FJ1
Braun, S; Browman, GP; Burstein, HJ; Chlebowski, RT; Cobleigh, MA; Edge, SB; Goldstein, LJ; Gralow, J; Hudis, C; Ingle, JN; Langer, AS; Mamounas, EP; Perotti, J; Powles, TJ; Pritchard, KI; Whelan, TJ; Winer, EP1
Albers, N; Freiberg, C; Roth, C; Zappel, H1
Bramwell, V; Vandenberg, T; Winquist, E1
Bruntsch, U1
Beat, T1
Howell, A2
Faulds, DM; Wellington, K1
Gluck, S2
Mokbel, K; Singh-Ranger, G2
Hakamata, Y; Hozumi, Y; Nagai, H; Ogura, S; Sasanuma, H1
Robertson, JF1
Jordan, VC2
Coleman, RE1
Aumiller, J3
Martín de Vidales, C; Pérez-Torrubia, A; Zapatero, A1
Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y1
Buzdar, A1
Brown, P; Wu, K1
Dranitsaris, G; Trudeau, M; Verma, S1
Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E1
Dimmer, C; Goodare, H; Page, K1
Thornton, H1
Höffken, K; Sayer, HG1
Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B2
Rose, C1
Brodie, AH; Mouridsen, HT1
Thomas, R1
Cuzick, J3
Dixon, JM; Jackson, J; Miller, WR1
Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R1
Aapro, MS; Forbes, JF1
Carlson, RW; Henderson, IC1
Hortobagyi, GN1
Gerber, B1
Fleming, GF1
Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T1
Baum, M; Buzdar, A; Howell, A1
Dixon, JM; Jackson, J; Miller, WR; Renshaw, L1
Nabholtz, JM2
Fallowfield, L; Howell, T; Jenkins, V; Shilling, V1
Davidson, NE; Emens, L; Visvanathan, K1
Pritchard, KI1
Smith, IE1
Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE1
Bianco, AR; Clack, G; Coibion, M; Cuzick, J; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M1
Buzdar, A; Jones, D; Simons, WR1
Goss, PE; Strasser-Weippl, K1
Fallowfield, L; Howell, A; Hutton, S; Jenkins, V; Shilling, V1
Aihara, T; Morino, H; Munakata, S; Takatsuka, Y1
Cheung, KL; Forward, DP; Jackson, L; Robertson, JF1
Kammerer, S1
Eiermann, W1
Domont, J; Khayat, D; Namer, M; Spano, JP1
Kawakami, M; Saji, S; Toi, M1
Curran, MP; McKeage, K; Plosker, GL1
Baron, M; d'Anjou, J; Dessogne, P1
Campos, SM1
Arora, A; Potter, JF1
Chaudri-Ross, HA; Mouridsen, HT1
Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B1
Clemons, M; Coleman, RE; Verma, S1
Sainsbury, R1
Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F1
Aebi, S; Baumann, ChK1
Cuzick, J; Locker, GY; Sainsbury, JR1
Tobias, JS2
Boccardo, F2
Hillner, BE1
Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL1
Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I1
Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M2
Cella, D; Cuzick, J; Fallowfield, L; Francis, S; Howell, A; Locker, G1
Caruggi, M; Colombo, G; Marchetti, M1
Hiura, M; Nogawa, T; Oshita, T; Yokoyama, T1
Johnston, S; Stebbing, J1
Casper, RF; Diamond, MP; Mitwally, MF1
Duffy, SR; Taylor, L1
Dowsett, M1
Buzdar, A; Macahilig, C1
de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B1
Harwood, KV1
Fentiman, IS1
Travis, K1
Battaglia, M; Bertaccini, A; Boccardo, F; Comeri, G; Conti, G; Di Tonno, P; Durand, F; Ferraris, V; Galassi, P; Macchiarella, A; Manganelli, A; Martorana, G; Montefiore, F; Muscas, G; Potenzoni, D; Rubagotti, A; Selvaggi, FP; Siragusa, A; Zattoni, F1
Gallo, J; Morris, T; Saltzstein, D; Sieber, P1
Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE1
Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G2
Clemons, MJ; Freedman, OC; Verma, S1
Miller, DS; Rao, GG1
Michaud, LB1
Bershtein, LM; Kovalevskii, AY; Poroshina, TE; Semiglazov, VF; Tsyrlina, EV; Zhil'tsova, EK; Zimarina, TS1
Ayaori, M; Hiraide, H; Kusuhara, M; Mochizuki, H; Ohsuzu, F; Sato, K; Sawada, S; Tamaki, K; Yonemura, A1
Angeles Victoria, L; Basavilvazo Rodríguez, MA; Castelazo Rico, G; Hernández Valencia, M; Molotla Xolalpa, D; Zárate, A1
Jakesz, R1
Chen, S; Itoh, T; Karlsberg, K; Kijima, I; Smith, D; Ye, J; Yuan, YC1
Boccardo, F; Conti, G; Del Monaco, D; Manganelli, A; Potenzoni, D; Rubagotti, A1
Jones, SE; Pippen, J1
Brown, P; Kalidas, M1
Dodwell, D; Vergote, I1
Ingle, JN; Suman, VJ1
Ponzone, R; Sismondi, P1
Hamilton, AL; Nordman, IC; Spillane, AJ1
Ashley, SE; Blohmer, JU; Boeddinghaus, I; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Skene, A; Smith, IE; Walsh, G1
Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S1
Amadori, D; Amoroso, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Puntoni, M; Restuccia, N; Rinaldini, M; Romeo, D; Rubagotti, A; Scali, S; Sismondi, P1
Banerjee, S; Barker, P; Dowsett, M; Folkerd, L; Iqbal, J; Smith, IE1
Gradishar, WJ2
Kopans, DB; Ryan, PD; Sgroi, DC1
Thönnessen, D; Wenz, F1
Glassman, R; Stebbing, J1
Dickler, M1
Esteva, FJ; Hortobagyi, GN1
Attilakos, G; Fox, R1
Baum, M; Cuzick, J; Dowsett, M; Houghton, J; Howell, T; Wale, C1
Abram, P; Vergote, I1
Chen, S; Itoh, T; Kijima, I1
Howell, A; Locker, GY1
Denes, AE1
Demonty, G1
Sereda, D; Werth, VP1
A'Hern, R; Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G1
Buzdar, AU; Cuzick, J1
Gerber, B; Janni, W; Krause, A; Kundt, G; Makovitzky, J; Mylonas, I; Reimer, T1
Gltick, S1
Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F1
Rocchi, A; Verma, S1
Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y1
Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P1
Grana, G1
Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS1
Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C1
Amadori, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Restuccia, N; Rinaldini, M; Rubagotti, A; Scali, S; Sismondi, P1
Duffy, MJ1
Brown, MM; Manquez, ME; Shields, CL; Shields, JA1
Buzdar, AU; Cuzick, J; Guastalla, JP; Nabholtz, JM1
Adams, JE; Clack, G; Cuzick, J; Dowsett, M; Eastell, R; Hannon, RA1
Buzdar, A; Cuzick, J; Distler, W; Hoctin-Boes, G; Houghton, J; Howell, A; Locker, GY; Nabholtz, JM; Wale, C1
Dewar, R; Rayson, D; Skedgel, C; Younis, T3
Borstnar, S; Cufer, T; Mrhar, A; Piskur, P; Sonc, M1
Dodwell, D; Pippen, J1
Barker, P; Cella, D; Cuzick, J; Fallowfield, L; Howell, A; Locker, G1
Annemans, L; Moeremans, K1
DiLeonardo, M; Gibbons, G; Resnik, KS1
Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I1
Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M1
Chu, QD; Li, BD; McDonald, JC1
Kaya, U; Kuscu, E; Oktem, M; Ozen, O; Zeyneloglu, HB1
Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Yoshida, Y1
A'Hern, R; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G1
Lewis, S1
Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K1
Cella, D; Dobrez, D; Gandhi, SK; Locker, GY; Mansel, R; Sorensen, S1
Ellis, MJ; Rigden, CE1
Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT1
Cianfrocca, M; Wolff, AC1
Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG1
Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C1
Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Fukutomi, T; Hasegawa, T; Kinoshita, T; Omatsu, M; Seki, K; Shien, T; Shimizu, C; Terada, K1
Lian, ZQ; Yang, MT1
Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y1
Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D1
Kafy, S; Tulandi, T1
Bell, R; Lewis, J1
Lin, NU; Winer, EP1
Eidtmann, H; Gademann, G; Hilfrich, J; Jonat, W; Kaufmann, M; von Minckwitz, G; Zuna, I1
Gralow, JR1
Barghout, V; Delea, T; Karnon, J1
Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L1
Benedict, A; Fallowfield, L; Jones, D; Locker, G; Mansel, R1
Basso, AD; Black, S; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Robert Bishop, W; Taylor, SA1
Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T1
Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M1
Cufer, T1
Fabian, CJ1
O'Shaughnessy, J1
Perez, EA1
Jahanzeb, M1
Schagen, SB; Schilder, CM1
Borg, S; De Lafontan, B; Laroche, M; Lassoued, S; Roché, H1
Antoni, G; Bollet, MA; Campana, F; Cottu, P; Dendale, R; Fourquet, A; Kirova, YM; Laki, F; Pierga, JY; Salmon, R; Sigal-Zafrani, B1
Altundag, K; Dizdar, O; Harputluoglu, H1
Brodie, AM; Buzdar, AU; Come, SE; Coombes, RC; Goss, PE; Ingle, JN; Johnston, SRD; Miller, WR; Pritchard, KI; Winer, EP; Zujewski, JA1
Prowell, TM; Stearns, V1
Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C1
Akiyama, F; Ikeda, T; Imoto, S; Inaji, H; Kurosumi, M; Noguchi, S; Sakamoto, G; Takatsuka, Y; Tsuda, H; Watanabe, T1
Wengström, Y1
Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS1
Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M1
Miller, WR1
Toi, M1
Allred, C; Bishop, H; Buzdar, A; Carder, P; Cussac, AL; Cuzick, J; Dowsett, M; Ellis, I; Forbes, J; Houghton, J; Knox, F; Knox, J; Larsimont, D; Mallon, E; Quinn, E; Salter, J; Sasano, H; Speirs, V; Wale, C; Williams, N1
Blackwell, KL; Herold, CI2
Carpenter, R1
Adams, JE; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Hannon, RA; Howell, A; Mackey, JR1
Aapro, M1
Pennery, E1
Ucci, G1
Coates, A; Mouridsen, H; Thürlimann, B1
A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O1
A'hern, R; Banerjee, S; Dowsett, M; Ghazoui, Z; Martin, LA; Pancholi, S; Smith, IE1
Eisner, A; Falardeau, J; Toomey, MD; Vetto, JT1
Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P1
Fields, MM; Mellington, TE1
Gligorov, J; Nabholtz, JM1
Chen, S; Lui, K; Mori, T; Tamura, T; Zhou, D1
Bogliolo, S; Costantini, S; Dugnani, MC; Ferrero, S; Moioli, M; Papadia, A; Valenzano Menada, M1
Grossman, J; Hahn, BH; La Cava, A; Wong, M1
Nagykálnai, T1
Kahán, Z1
Bianco, AR; Buzdar, AU; Cuzick, J; Eastell, R; Forbes, JF; Sapunar, F; Sestak, I1
Eisner, A; Falardeau, J; Thielman, EJ; Vetto, JT1
Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P1
Chlebowski, RT2
Chlebowski, RT; Col, N1
Gurwitz, D; Newman, W1
A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A1
Boyle, F; Butow, P; Coates, A; Forbes, JF; Juraskova, I; Lopez, A; McCarthy, N; Reaby, L; Seccombe, M1
Cella, D; Cuzick, J; Fallowfield, L; Sestak, I1
Baum, M; Cuzick, J; Distler, W; Duffy, SR; Howell, A1
Needleman, SJ; Tobias, JS1
Bielajew, C; Collins, B; Mackenzie, J; Stewart, A; Verma, S1
Callam, M; Glen, J; Thomas, RJ; Williams, M1
Albert, US; Hadji, P; Holzhauer, W; Kalder, M; Wagner, U; Ziller, M; Ziller, V1
Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C1
Alacacioğlu, A; Bilgi, O; Erikçi, AA; Kandemir, EG; Karagöz, B; Ozgün, A; Sayan, O1
Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K1
Cobb, P; Henry, D; Houts, AC; Kulig, K; Schwartzberg, LS; Senecal, F; Stepanski, EJ; Walker, MS1
Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kouno, T; Shibata, T; Shien, T; Shimizu, C; Terada, K; Yoshida, M; Yoshimura, K1
Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G1
Wenz, F1
Aebi, S; Gelber, RD1
Calabrich, A; Katz, A; Saad, ED1
Gerber, B; Reimer, T1
Dong, PW; Li, LN1
Agrawal, A; Aleskandrany, M; Cheung, KL; Ellis, IO; Green, AR; Hassell, K; Morgan, DA; Okunade, G; Paish, EC; Winterbottom, L; Ying, M1
Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P1
Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G1
Amakye, D; Bauerfeind, I; Buzdar, A; Chia, S; Chlebowski, R; Cutuli, B; Cuzick, J; Hadji, P; Linforth, R; Maass, N; Noguchi, S; Robidoux, A; Verma, S1
Cuzick, J; Sapunar, F; Sestak, I1
Gobello, C; Gonzalez, G; Guendulain, C; Maffrand, C1
Noguchi, S; Taguchi, T1
Lazarus, P; Sun, D1
Bonanni, B; Cassano, E; Cazzaniga, M; Decensi, A; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lien, EA; Luini, A; Macis, D; Oldani, S; Pelosi, G; Serrano, D1
Chen, S; Masri, S; Phung, S; Wang, X1
Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O1
Baumann, CK; Castiglione-Gertsch, M1
Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P1
Aldemir, M; Altuğ, U; Cakan, M; Topcuoglu, M1
Beriwal, S; Bhargava, R; Dabbs, DJ; O'Connor, SM1
Baehner, FL; Baum, M; Bugarini, R; Buzdar, A; Cuzick, J; Dowsett, M; Dunbier, A; Forbes, J; Howell, A; Mallon, EA; Quinn, E; Salter, J; Shak, S; Wale, C1
Maidment, SL1
Crossley, M; Lejbak, L; Vrbancic, M1
Beckmann, MW; Benedict, A; Buchholz, S; Distler, W; Hadji, P; Harbeck, N; Jonat, W; Kaufmann, M; Kreienberg, R; Kreif, N; Lux, MP; Possinger, K; Raab, G; Schneeweiss, A; Tesch, H; Weyers, G; Wöckel, A1
Abe, H; Aihara, T; Aogi, K; Hisamatsu, K; Hozumi, Y; Imoto, S; Ito, T; Iwata, H; Masuda, N; Mitsuyama, S; Mukai, H; Nakagami, K; Ogino, N; Ohashi, Y; Ohsumi, S; Shimizu, C; Takatsuka, Y; Tamura, M; Tanaka, S; Watanabe, T; Yamaguchi, T1
Fox, KR1
Cuzick, J; Distler, W; Dowsett, M; Forbes, JF; Howell, A; Sestak, I1
Goodwin, PJ; Pritchard, KI1
Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D1
Mouridsen, HT1
Agrawal, K; Mortimer, JE; Onami, S; Pal, SK1
Bianco, AR; Clack, G; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Wells, M1
Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B1
Dixon, JM; Dixon, OM; Fallowfield, LJ; Langridge, C; Macaskill, EJ; McCaig, F; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, OE1
Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L1
Mylander, WC; Rosman, M; Tafra, L1
Amant, F; Berteloot, P; Blomme, C; De Jonge, E; Depypere, H; Neven, P; Timmerman, D; Van Calster, B; Van de Putte, G; Van den Broecke, R; Van Ginderachter, J; Van Huffel, S; Vergote, I; Vlaemynck, G; Vlasselaer, J1
Facina, G; Gebrim, LH; Logullo, AF; Mattar, A; Nonogaki, S; Soares, FA1
Buzdar, AU; Kelly, CM2
Adams, J; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Howell, A; Mackey, J1
Tang, SC1
Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S1
Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Sestak, I1
Gnant, M1
Kawachi, H; Kubota, K; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Yamamoto, K1
Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H1
Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S1
Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H2
Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H1
Aihara, T; Hozumi, Y; Mukai, H; Ohashi, Y; Ohsumi, S; Shimozuma, K; Shinji, M; Takatsuka, Y1
Doughty, JC1
Tannock, IF1
Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H1
Buzdar, AU; Cuzick, J; Dowsett, M; Forbes, J; Howell, A; Mallon, E; Pineda, S; Salter, J; Zabaglo, L1
Baigent, A; Lashen, H1
Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R1
Bjelic-Radisic, V; Dubsky, P; Fesl, C; Gnant, M; Greil, R; Königsberg, R; Marth, C; Mlineritsch, B; Pfeiler, G; Pöstlberger, S; Samonigg, H; Seifert, M; Singer, CF; Steger, GG; Stoeger, H; Taucher, S1
Bauernhofer, T; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Forsthuber, EP; Gnant, M; Greil, R; Heck, D; Hochreiner, G; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pristauz, G; Seifert, M; Steger, G; Stoeger, H1
Allawi, Z; Baum, M; Cuzick, J1
Ciruelos Gil, EM; Fernández Martínez, R; Fernández Pérez, I; Garcerá Juan, S; Illarramendi Mañas, JJ; Iranzo González Cruz, V; Lao Romera, J; Peláez Fernández, I; Puertolas Hernández, TJ; Sampedro Gimeno, T1
Alba Conejo, E; Bayo Calero, J; de la Cabeza Lomas Garrido, M; de la Haba Rodríguez, J; de Toro Salas, R; González Mancha, R; Martínez Guisado, A; Ruíz Borrego, M; Sánchez Muñoz, A1
Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E1
Hurria, A1
Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Ring, A; Sestak, I1
Bago-Horvath, Z; Böhm, G; Dubsky, P; Filipits, M; Gnant, M; Greil, R; Gruber, C; Haid, A; Jakesz, R; Jasarevic, Z; Jelen, A; Kemmerling, R; Pöstlberger, S; Rudas, M; Singer, CF1
Schmidt, C1
Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K1
A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M1
Akiyama, F; Fujiwara, Y; Ikeda, T; Imoto, S; Inaji, H; Iwata, H; Mitsuyama, S; Miyoshi, K; Noguchi, S; Takatsuka, Y; Tamura, M1
Hawkins, N; Veenstra, D; Woods, B1
Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL1
Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H1
Frederix, GW; Hövels, AM; Raaijmakers, JA; Schellens, JH; Severens, JL1
Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y1
Burstein, HJ; Griggs, JJ1
Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C1
Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN1
Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L1
Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I1
Mewar, D; Michael, B; Tunn, E; Williams, S1
Acar, H; Ata, O; Toy, H; Yavas, C; Yavas, G; Yuce, D1
Hayashi, N; Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Tsuda, H; Yanagita, Y1
Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE1
Magee, PJ; Rowland, I1
Garcia, PL; Gomes, FP1
Tung, N1
Bong, JG; Jeong, YJ; Kwon, HJ; Park, SH; Park, YS; Shin, IH1
Boccardo, F; Bordonaro, R; Fini, A; Guglielmini, P; Massidda, B; Orzalesi, L; Porpiglia, M; Roagna, R; Rubagotti, A; Serra, P; Ucci, G1
Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y1
Aapro, M; Bartlett, JM; Coleman, RE; Markopoulos, C; Putter, H; van de Velde, CJ1
Banerjee, M; Gersch, C; Giacherio, D; Hayes, DF; Henry, NL; McConnell, D; Partridge, AH; Pearlman, M; Schott, AF; Stearns, V; Xia, R1
Cowens, JW; Cuzick, J; Dowsett, M; Dunbier, AK; Ferree, S; Lopez-Knowles, E; Schaper, C; Sestak, I; Sidhu, K; Storhoff, J1
Afentakis, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, J; Howell, T; Salter, J; Sestak, I1
Cuzick, J; Dowsett, M; Dunbier, A; Erlander, MG; Goss, PE; Lopez-Knowles, E; Schnabel, CA; Schroeder, B; Sestak, I; Sgroi, DC; Sidhu, K; Zhang, Y1
Gebrim, LH; Logullo, AF; Madeira, M; Mattar, A; Soares, FA1
Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE1
Mehta, A; Tripathy, D1
Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S1
Frederix, GW; Hövels, AM; Huitema, AD; Raaijmakers, JA; Schellens, JH; Severens, JL; van Hasselt, JG1
Bago-Horvath, Z; Balic, M; Bartsch, R; Cowens, JW; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Knauer, M; Kwasny, W; Liu, S; Mlineritsch, B; Nielsen, TO; Ressler, S; Rudas, M; Schaper, C; Singer, C; Steger, G; Stoeger, H; Storhoff, J1
Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C1
Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C1
Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M1
A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE1
Brufsky, AM1
Agrawal, A; Cheung, KL; Gutteridge, E; Marenah, C; Mathew, J; Prinsloo, P; Robertson, JF1
Dryden, R; Harrow, A; McCowan, C; Parsons, M; Radley, A; Thompson, AM; Wells, M1
Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y1
Andò, S; Barone, I; Brown, PH; Fuqua, SA; Iacopetta, D; O'Malley, BW; Rechoum, Y; Rovito, D; Weigel, NL1
Campos-Gómez, S; Chapa-Ibargüengoitia, M; de la Peña-Lopez, R; Dorantes-Heredia, R; Flores-Arredondo, JH1
Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H1
Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ1
Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I1
Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Lopez-Knowles, E; Schaper, C; Sestak, I1
Albertini, S; Kelly, E; Lu, CY; Vitry, A1
Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I1
Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V1
Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P1
Barbie, TU; Ma, C; Margenthaler, JA1
Bevers, TB1
Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H1
Chang, CH; Chen, SJ; Liu, CY1
Audisio, R; Cheung, KL; Collins, K; Morgan, JL; Reed, MW; Robinson, TG; Wyld, L1
Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E1
Buist, MR; Kenter, GG; van der Velden, J; van Driel, WJ; van Lonkhuijzen, LR; van Meurs, HS1
Colleoni, M; Munzone, E1
Dowsett, M; Yeo, B1
Kuerer, H; Mitchell, KB1
Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y1
Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G1
Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF2
Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P1
Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M1
Amaral, C; Correia-da-Silva, G; Sobral, AF; Teixeira, N1
Cuzick, J; Dowsett, M; Schnabel, CA; Schroeder, BE; Sestak, I; Sgroi, D; Zhang, Y1
Gilarranz, YJ; Lopez-Tarruella, S; Martin, M1
Altinok, AY; Altug, T; Azria, D; Bese, NS; Ober, A; Ozsahin, EM; Sut, N; Yildirim, S1
Buus, R; Cuzick, J; Denkert, C; Dowsett, M; Dubsky, P; Krappmann, K; Kronenwett, R; Petry, C; Scheer, M; Sestak, I1
Brufsky, AM; Davidson, NE1
Arpino, G; De Placido, G; De Placido, S; De Rosa, P; Locci, M; Nazzaro, G; Pagano, T; Schettini, F; Vallone, R1
Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P1
Bodurka, DC; Coleman, RL; Gershenson, DM; Lu, KH; Malpica, A; Sun, CC1
Corrigan, MA; Jinih, M; O'Reilly, S; Redmond, HP; Relihan, N1
Giorgadze, E; Khachidze, N; Tsagareli, M1
Alvarez, CA; Balasubramian, BA; Jean, GW; Murphy, CC; Tiro, JA1
Cohen, PR1
Carpenter, NA; Crook, EK1
Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y1
Ahmed, I; Bartlett, JMS; Brookes, CL; Cuzick, J; Dell'Orto, P; Dowsett, M; Forbes, JF; Mallon, EA; Putter, H; Rea, DW; Regan, MM; Sestak, I; Seynaeve, C; Thürlimann, B; Van de Velde, CJH; Viale, G1
Ellis, MJ; Goncalves, R; Reinert, T1
Andrade, DB; Barros-Oliveira, MDC; Borges, RS; Borges, US; Costa-Silva, DR; Silva, BBD; Silva, JM; Tavares, CB1
Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG1
Armstrong, DK; Bergstrom, J; DeBernardo, R; Fader, AN; Gaillard, S; Jernigan, A; Levinson, KL; Michener, C; Ricci, S; Roche, KL; Rose, PG; Shih, IM; Stone, RL; Tanner, EJ; Wang, TL; Wethingon, S; Yang, B; Zhang, G1
Austin, ED; Brittain, EL; Chen, X; Farber-Eger, EH; Fessel, JP; Hemnes, AR; Loyd, JE; Talati, M; West, J1
He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S1
Cuzick, J; Dowsett, M; Heindl, A; Naidoo, K; Sestak, I; Yuan, Y1
de Boer, M; De Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG2
Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Smith, SG1
Chung, C1
Clayman, E; Huber, KM; Kumar, A; Smith, P1
Baehner, FL; Buus, R; Cuzick, J; Denkert, C; Dowsett, M; Dubsky, P; Ferree, S; Kronenwett, R; Mallon, E; Schnabel, C; Sestak, I; Sgroi, D1
Amoroso, D; Arpino, G; Bernardo, A; Bisagni, G; Carlini, P; Cognetti, F; Cogoni, AA; De Laurentiis, M; De Placido, S; Del Mastro, L; Foglietta, J; Frassoldati, A; Gallo, C; Gori, S; Gravina, A; Lai, A; Laudadio, L; Lauria, R; Lorusso, V; Mocerino, C; Montemurro, F; Moretti, G; Moscetti, L; Nuzzo, F; Perrone, F; Riccardi, F; Rizzo, S; Russo, A; Sarobba, MG; Verusio, C1
Dirix, LY1
de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kitzen, JJEM; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH1
Evans, DG; Howell, A; Howell, SJ1
Colleoni, M; Cuzick, J; Dodson, A; Dowsett, M; Regan, MM; Sestak, I; Thürlimann, B; Viale, G1
Brentnall, AR; Buus, R; Cheang, MCU; Cuzick, J; Dowsett, M; Gao, Q; Khabra, K; Klintman, M; Sestak, I; Yeo, B1
Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J1
Chang, B; Fan, X; Jiang, X; Kariminia, S; Li, L; Li, Q; Li, T; Li, Y; Wu, S; Zhang, J1
Bailey, C; Birkett, J; De Grève, J; De Vos, FYFL; Dean, E; Dirix, L; Goessl, C; Grundtvig-Sørensen, P; Italiano, A; Jerusalem, G; Learoyd, M; Leunen, K; Molife, LR; Plummer, R; Rolfo, C; Rottey, S; Spencer, S; Spicer, J; Verheul, HM1
Kamaraju, S; Laud, P; Nattinger, AB; Neuner, J; Shi, Y; Smith, E1
Drokow, EK; Li, Z; Liu, J; Ma, X; Ren, J; Shao, S; Shi, X; Tan, L; Xue, C; Yan, Y; Zhang, L; Zhang, X; Zhang, Y1
Boyd, R; Campbell, AM; Carson, H; Elliott, C; Gallagher, R; Harkin, DP; McIntosh, SA; Morris, M; Savage, KI; Wielogorska, E1
de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH1
Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N1
Augustine, TN; Chetty, N; Dix-Peek, T; Duarte, R; Pather, K1
Daniels, B; Pearson, SA; Preen, DB; Tang, M; Tervonen, HE1
Alarid, ET; Arendt, LM; Beebe, DJ; Johnson, BP; Morgan, MM1
DiNardo, D; Farkas, A; Merriam, S; Vanderberg, R1
Barron, S; Buus, R; Cuzick, J; Dowsett, M; Dynoodt, P; Fender, B; Gallagher, WM; Loughman, T; O'Leary, D; Ruiz, CL; Sestak, I; Wang, CA1
Chumsri, S; Thompson, EA1
Chen, J; Fan, Y; He, T; Huang, Q; Li, P; Lv, Q; Wu, Y; Xiang, M; Yang, D; Yang, W; Zhang, X; Zhou, R1
Carpi, A; Ferrari, P; Morganti, R; Nicolini, A; Rossi, G1
Petit, T1
Aebersold, DM; Albrecht, C; Böhmer, D; Flentje, M; Ganswindt, U; Ghadjar, P; Höcht, S; Hölscher, T; Müller, AC; Niehoff, P; Pinkawa, M; Sedlmayer, F; Wiegel, T; Zips, D1
Duma, MN; Krug, D1
Avarisli, NA; Bicer, BK; Bicer, T; Dogan, AS; Gurdal, C; Imamoglu, GI; Kabatas, N1
Schenke, H; Trabitzsch, J1
DiNome, ML; Ganz, PA; Graham, D1
Baehner, FL; Buus, R; Cuzick, J; Dowsett, M; Ferree, S; Kronenwett, R; Mallon, EA; Schnabel, CA; Sestak, I1
Ferracini, AC; Juliato, CRT; Mazzola, PG; Medeiros, LM; Souza, CM; Stahlschmidt, R2
Bogliolo, S; Carletti, GV; Cassani, C; De Silvestri, A; Dominoni, M; Gardella, B; Spinillo, A1
Balic, M; Bartsch, R; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Herz, W; Moinfar, F; Rudas, M; Schaper, C1
Agostinetto, E; de Azambuja, E; Debien, V; Lambertini, M; Marta, GN; Piccart-Gebhart, M1
Gilman, EA; Hofstatter, EW; Mussallem, DM; Pruthi, S1
Abramowitz, J; Chan, AVC; Ganji, N; Mirfakhraee, S1
Balic, M; Bartsch, R; Bjelic-Radisic, V; Brunner, C; Deutschmann, C; Egle, D; Fesl, C; Fitzal, F; Gampenrieder, SP; Gnant, M; Greil, R; Greil-Ressler, S; Haslbauer, F; Heck, D; Jakesz, R; Kacerovsky-Strobl, S; Manfreda, D; Melbinger-Zeinitzer, E; Rinnerthaler, G; Sevelda, P; Singer, CF; Soelkner, L; Steger, GG; Suppan, C; Thaler, J; Trapl, H; Wette, V; Wieder, U; Wimmer, K1
Bago-Horvath, Z; Balic, M; Barron, S; Dubsky, P; Egle, D; Filipits, M; Fitzal, F; Gallagher, WM; Gnant, M; Greil, R; Halper, S; Hlauschek, D; Hulla, W; Kainz, V; Loughman, T; O'Leary, D; Regitnig, P; Rudas, M; Singer, CF1
Adams, S; Klar, N1
Gong, S; Hong, K; Liang, JJ; Liu, TY; Qin, KM; Xie, BH; Yan, JJ; Yang, L; Yin, YP; Yu, WL; Zhou, HB1
Ng, BP; Park, C; Park, SK; Woo, A1
Buus, R; Chu, K; Colleoni, M; Cuzick, J; Di Fiore, PP; Disalvatore, D; Dowsett, M; Freddi, S; Maisonneuve, P; Montani, F; Pece, S; Sestak, I; Tillhon, M; Veronesi, P; Viale, G1
Elancheran, R; Maruthanila, VL; Mirunalini, S1
Acconcia, F1
Han, S; Heo, JH; Mehta, S; Park, C; Spencer, JC1
Castro, RCMB; Corpes, EF; Fernandes, AFC; Leite, KM; Martins, MCT; Santos, CPRSD; Silva, DMD; Vieira, MM; Yanez, RJV1
Egawa, C; Hasegawa, Y; Higaki, K; Hozumi, Y; Iijima, K; Iwase, T; Komoike, Y; Masuoka, H; Mukai, H; Nakamura, T; Ohtani, S; Ohtsu, H; Saji, S; Sato, Y; Takei, H; Tanabe, M; Tanaka, M; Yanagita, Y1
Al Hussein Al Awamlh, B; Barocas, DA; Chang, SS; Cortese, BD; Dusetzina, SB; Luckenbaugh, AN; Penson, DF; Stimson, CJ; Talwar, R1
Salmon, RJ1
Arnachellen, D; Augustine, TN; Pillay, K; Xulu, KR1
Calsavara, VF; Cecchini, RS; Diniz, MA; Ganz, PA; Gresham, G; Hays, RD; Henry, NL; Kim, S; Luu, M; Rogatko, A; Tighiouart, M; Yothers, G1
Chavez-MacGregor, M; Freedman, RA; Glass, C; Jones, A; Kantor, O; King, TA; Leonard, SJ; Mayer, EL; Mittendorf, EA; Newman, LA; Ogayo, ER1
Mahase, E1

Reviews

155 review(s) available for anastrozole and tamoxifen

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
    Journal of surgical oncology, 1997, Volume: 66, Issue:3

    Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles

1997
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles

1998
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles

1999
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
    Endocrine-related cancer, 1999, Volume: 6, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles

1999
Use of aromatase inhibitors in breast carcinoma.
    Endocrine-related cancer, 1999, Volume: 6, Issue:1

    Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles

1999
[Chemo/endocrine therapy for breast cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:8

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Gonadotropin-Releasing Hormone; Humans; Nitriles; Tamoxifen; Triazoles

2000
[Developments of hormonal agents for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:7

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles

2001
New combinations with Herceptin in metastatic breast cancer.
    Oncology, 2001, Volume: 61 Suppl 2

    Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine

2001
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:4

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles

2001
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
    Breast cancer (Tokyo, Japan), 2001, Volume: 8, Issue:4

    Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles

2001
A summary of second-line randomized studies of aromatase inhibitors.
    The Journal of steroid biochemistry and molecular biology, 2001, Volume: 79, Issue:1-5

    Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2001
A vision for the future?
    British journal of cancer, 2001, Volume: 85 Suppl 2

    Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitriles; Tamoxifen; Triazoles

2001
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Suppl

    Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles

2001
Aromatase inhibitors continue their ATAC on tamoxifen.
    Trends in molecular medicine, 2002, Volume: 8, Issue:4 Suppl

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles

2002
Antiaromatase agents: evolving role in adjuvant therapy.
    Clinical breast cancer, 2002, Volume: 3, Issue:1

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2002
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
    Minerva ginecologica, 2002, Volume: 54, Issue:2

    Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles

2002
[Antiestrogen therapy in the treatment of breast neoplasms].
    Minerva ginecologica, 2002, Volume: 54, Issue:3

    Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles

2002
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
    Expert review of anticancer therapy, 2001, Volume: 1, Issue:2

    Topics: Adjuvants, Pharmaceutic; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Triazoles

2001
Evolving uses of hormonal agents for breast cancer therapy.
    Clinical therapeutics, 2002, Volume: 24 Suppl C

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Nitriles; Tamoxifen; Toremifene; Triazoles

2002
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Aug-01, Volume: 20, Issue:15

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Evidence-Based Medicine; Expert Testimony; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Triazoles

2002
Anastrozole: in early breast cancer.
    Drugs, 2002, Volume: 62, Issue:17

    Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Enzyme Inhibitors; Female; Half-Life; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles

2002
Breast cancer chemoprevention--an update.
    Current medical research and opinion, 2002, Volume: 18, Issue:6

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Forecasting; Genes, BRCA2; Humans; Incidence; Middle Aged; Nitriles; Odds Ratio; Receptors, Estrogen; Tamoxifen; Triazoles

2002
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Female; Humans; Nitriles; Tamoxifen; Triazoles; United States

2002
Adjuvant endocrine therapy in postmenopausal breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1 Pt 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles

2003
Current and future status of adjuvant therapy for breast cancer.
    Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Forecasting; Humans; Nitriles; Osteoporosis; Receptors, Estrogen; Tamoxifen; Triazoles

2003
Is tamoxifen the Rosetta stone for breast cancer?
    Journal of the National Cancer Institute, 2003, Mar-05, Volume: 95, Issue:5

    Topics: Acetyltransferases; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Metaphor; Nitriles; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 3; Oncogene Proteins; Phosphorylation; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Trans-Activators; Transcription Factors; Treatment Failure; Treatment Outcome; Triazoles

2003
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
    Revista clinica espanola, 2003, Volume: 203, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2003
Current status of endocrine therapy for breast cancer.
    Breast cancer (Tokyo, Japan), 2003, Volume: 10, Issue:2

    Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Climacteric; Female; Goserelin; Humans; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles

2003
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Clinical breast cancer, 2003, Volume: 4 Suppl 1

    Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States

2003
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
    Journal of the National Cancer Institute, 2003, Jun-04, Volume: 95, Issue:11

    Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Ki-67 Antigen; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2003
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles

2003
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays

2003
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2003, Volume: 163

    Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles

2003
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
    Expert opinion on drug safety, 2003, Volume: 2, Issue:1

    Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Metabolism; Nitriles; Patient Satisfaction; Quality of Life; Safety; Tamoxifen; Triazoles

2003
Should aromatase inhibitors replace tamoxifen?
    Drug and therapeutics bulletin, 2003, Volume: 41, Issue:8

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2003
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Breast cancer research and treatment, 2003, Volume: 80 Suppl 1

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles

2003
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Breast cancer research and treatment, 2003, Volume: 80 Suppl 1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Endocrine System; Female; Humans; Menopause; Neoplasm Metastasis; Nitriles; Patient Selection; Receptors, Estrogen; Tamoxifen; Triazoles

2003
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles

2003
[Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].
    Zentralblatt fur Gynakologie, 2003, Volume: 125, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2003
Role of anastrozole in adjuvant therapy for postmenopausal patients.
    Seminars in oncology, 2003, Volume: 30, Issue:5 Suppl 16

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles

2003
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:3-5

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles

2003
New findings about endocrine therapy for breast cancer.
    Breast (Edinburgh, Scotland), 2003, Volume: 12, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2003
The best use of adjuvant endocrine treatments.
    Breast (Edinburgh, Scotland), 2003, Volume: 12, Issue:6

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Ovary; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles

2003
Challenges in the endocrine management of breast cancer.
    Breast (Edinburgh, Scotland), 2003, Volume: 12 Suppl 2

    Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Mastectomy, Segmental; Mice; Middle Aged; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom

2003
Focus on anastrozole and breast cancer.
    Current medical research and opinion, 2003, Volume: 19, Issue:8

    Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Enzyme Inhibitors; Estrogens; Female; Goserelin; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Triazoles

2003
[Neoadjuvant endocrine therapy for breast cancer: an overview].
    Bulletin du cancer, 2004, Volume: 91, Issue:1

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles

2004
[Controversies in endocrine therapy for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles

2004
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    Drugs, 2004, Volume: 64, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles

2004
Aromatase inhibitors for breast cancer in postmenopausal women.
    The oncologist, 2004, Volume: 9, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles

2004
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
    Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:4

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration

2004
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
    Cancer treatment reviews, 2004, Volume: 30, Issue:4

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2004
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
    British journal of cancer, 2004, May-04, Volume: 90, Issue:9

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2004
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:6

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles

2004
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
    The international journal of biochemistry & cell biology, 2004, Volume: 36, Issue:11

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles

2004
Current developments in hormonal therapy of breast cancer.
    Clinical breast cancer, 2004, Volume: 5 Suppl 1

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2004
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
    Clinical breast cancer, 2004, Volume: 5 Suppl 1

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2004
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
    Clinical breast cancer, 2004, Volume: 5 Suppl 1

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2004
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Cancer, 2004, Oct-01, Volume: 101, Issue:7

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles

2004
[Postoperative hormone (endocrine) therapy in endometrial carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Drug Therapy, Combination; Endometrial Neoplasms; Estrogens; Female; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Medroxyprogesterone Acetate; Nitriles; Postoperative Care; Tamoxifen; Treatment Outcome; Triazoles

2004
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles

2004
Breast cancer (metastatic).
    Clinical evidence, 2003, Issue:10

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles

2003
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    Bulletin du cancer, 2004, Volume: 91, Issue:12

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2004
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
    Clinical journal of oncology nursing, 2004, Volume: 8, Issue:6

    Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles

2004
Aromatase inhibitors and breast cancer: time for a change?
    International journal of clinical practice, 2004, Volume: 58, Issue:12

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles

2004
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles

2005
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Cancer treatment reviews, 2005, Volume: 31, Issue:1

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2005
Clinical applications of hormonal therapy in ovarian cancer.
    Current treatment options in oncology, 2005, Volume: 6, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leuprolide; Medroxyprogesterone; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Ovarian Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2005
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, Feb-01, Volume: 62, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2005
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
    Clinical breast cancer, 2005, Volume: 6 Suppl 1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2005
Aromatase inhibitors for the treatment and prevention of breast cancer.
    Clinical breast cancer, 2005, Volume: 6, Issue:1

    Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles

2005
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
    Cancer treatment reviews, 2005, Volume: 31, Issue:4

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2005
Aromatase inhibitors for therapy of advanced breast cancer.
    The Journal of steroid biochemistry and molecular biology, 2005, Volume: 95, Issue:1-5

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2005
The aromatase inhibitors in early breast cancer: who, when, and why?
    The Medical journal of Australia, 2005, Jul-04, Volume: 183, Issue:1

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Patient Selection; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2005
Anastrozole.
    Drugs of today (Barcelona, Spain : 1998), 2005, Volume: 41, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Recurrence; Survival Rate; Tamoxifen; Triazoles

2005
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:12

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2005
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Oncology, 2005, Volume: 69, Issue:1

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2005
Breast cancer (metastatic).
    Clinical evidence, 2005, Issue:13

    Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Nitriles; Progestins; Tamoxifen; Taxoids; Trastuzumab; Triazoles

2005
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Breast (Edinburgh, Scotland), 2005, Volume: 14, Issue:6

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2005
New developments in the treatment of postmenopausal breast cancer.
    Trends in endocrinology and metabolism: TEM, 2005, Volume: 16, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2005
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
    Breast (Edinburgh, Scotland), 2006, Volume: 15, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides

2006
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2006
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
    Clinical breast cancer, 2005, Volume: 6, Issue:4

    Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Nitriles; Research Design; Tamoxifen; Triazoles

2005
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Oncology, 2006, Volume: 70, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles

2006
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2006
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Journal of surgical oncology, 2006, Jun-01, Volume: 93, Issue:7

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2006
Anastrozole for breast cancer: recent advances and ongoing challenges.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Tamoxifen; Triazoles

2006
Time to response: comparison of fulvestrant and oral endocrine agents.
    Clinical breast cancer, 2006, Volume: 7, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2006
Bone safety of aromatase inhibitors versus tamoxifen.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006, Volume: 16 Suppl 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles

2006
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
    The Lancet. Oncology, 2006, Volume: 7, Issue:12

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles

2006
Adjuvant therapy for patients who have node-positive breast cancer.
    Advances in surgery, 2006, Volume: 40

    Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles

2006
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
    American heart journal, 2007, Volume: 153, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol; Estrogens; Female; Humans; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Thromboembolism; Triazoles; Triglycerides

2007
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
    Breast cancer (Tokyo, Japan), 2007, Volume: 14, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Triazoles

2007
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
    Current medical research and opinion, 2006, Volume: 22, Issue:12

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2006
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Ovariectomy; Ovary; Postmenopause; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles

2007
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    Nederlands tijdschrift voor geneeskunde, 2006, Dec-30, Volume: 150, Issue:52

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2006
[Advancement in endocrine therapy for breast cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2007
New advances in ovulation induction.
    Current opinion in obstetrics & gynecology, 2007, Volume: 19, Issue:3

    Topics: Anastrozole; Aromatase Inhibitors; Clomiphene; Estrogen Antagonists; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Letrozole; Nitriles; Ovary; Ovulation Induction; Pregnancy; Pregnancy Rate; Tamoxifen; Treatment Outcome; Triazoles

2007
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:26

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles

2007
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
    Ugeskrift for laeger, 2007, Sep-10, Volume: 169, Issue:37

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2007
Reducing the risk of late recurrence in hormone-responsive breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 8

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles

2007
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
    International journal of clinical practice, 2007, Volume: 61, Issue:12

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles

2007
Safety of aromatase inhibitors in the adjuvant setting.
    Breast cancer research and treatment, 2007, Volume: 105 Suppl 1

    Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles

2007
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Clinical therapeutics, 2007, Volume: 29, Issue:8

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles

2007
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
    Minerva ginecologica, 2007, Volume: 59, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cognition; Female; Gonadotropin-Releasing Hormone; Humans; Neuropsychological Tests; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2007
Effectively nursing patients receiving aromatase inhibitor therapy.
    Breast (Edinburgh, Scotland), 2008, Volume: 17, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Arthralgia; Atrophy; Breast Neoplasms; Cardiovascular Diseases; Comorbidity; Female; Hot Flashes; Humans; Lubricants; Neoplasm Recurrence, Local; Nitriles; Patient Education as Topic; Quality of Life; Tamoxifen; Triazoles; Vagina; Weight Gain

2008
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
    Cancer treatment reviews, 2008, Volume: 34, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2008
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
    Breast (Edinburgh, Scotland), 2008, Volume: 17 Suppl 1

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles

2008
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:7

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles

2008
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2008, Volume: 12, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2008
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
    Anti-cancer drugs, 2008, Volume: 19, Issue:4

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles

2008
Targeting breast cancer with hormonal treatment options.
    The Nurse practitioner, 2008, Volume: 33, Issue:5

    Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles

2008
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
    Reviews on recent clinical trials, 2006, Volume: 1, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles

2006
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
    Clinical breast cancer, 2008, Volume: 8, Issue:1

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles

2008
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
    Magyar onkologia, 2008, Volume: 52, Issue:2

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2008
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:12

    Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Early Diagnosis; Humans; Nitriles; Tamoxifen; Triazoles

2008
[Adjuvant breast cancer treatment with hormono-radiotherapy].
    Bulletin du cancer, 2009, Volume: 96, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2009
Breast cancer chemoprevention - a vision not yet realized.
    European journal of cancer care, 2009, Volume: 18, Issue:5

    Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles

2009
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
    Breast (Edinburgh, Scotland), 2009, Volume: 18 Suppl 2

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Secondary Prevention; Survival Analysis; Tamoxifen; Triazoles; Women's Health

2009
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles

2010
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Minerva ginecologica, 2009, Volume: 61, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genotype; Humans; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2009
Adjuvant endocrine therapy for early breast cancer: the story so far.
    Cancer investigation, 2010, Volume: 28, Issue:4

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles

2010
Question 2. Which medications effectively reduce pubertal gynaecomastia?
    Archives of disease in childhood, 2010, Volume: 95, Issue:3

    Topics: Anastrozole; Aromatase Inhibitors; Child; Estrogen Antagonists; Evidence-Based Medicine; Gynecomastia; Humans; Male; Nitriles; Puberty; Tamoxifen; Treatment Outcome; Triazoles

2010
Anastrozole.
    Expert opinion on drug safety, 2010, Volume: 9, Issue:6

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles

2010
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid

2010
When to start an aromatase inhibitor: now or later?
    Journal of surgical oncology, 2011, Jun-01, Volume: 103, Issue:7

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2011
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
    Steroids, 2011, Volume: 76, Issue:8

    Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles

2011
Preventive therapy for breast cancer: a consensus statement.
    The Lancet. Oncology, 2011, Volume: 12, Issue:5

    Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles

2011
Update on adjuvant hormonal treatment of early breast cancer.
    Advances in therapy, 2011, Volume: 28 Suppl 6

    Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2011
Initialization of adjuvant hormonal treatment for breast cancer.
    Advances in therapy, 2011, Volume: 28 Suppl 6

    Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Detection of Cancer; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2011
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2012, Volume: 15, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles

2012
Soy products in the management of breast cancer.
    Current opinion in clinical nutrition and metabolic care, 2012, Volume: 15, Issue:6

    Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-450 CYP1B1; Diet; Drug Interactions; Female; Humans; Incidence; Isoflavones; Meta-Analysis as Topic; Nitriles; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-mdm2; Receptor, ErbB-2; Recurrence; Risk Factors; Soy Foods; Tamoxifen; Triazoles

2012
Pharmacogenomics of endocrine therapy in breast cancer.
    Journal of human genetics, 2013, Volume: 58, Issue:6

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2013
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1

    Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles

2014
Current concepts in breast cancer chemoprevention.
    Polskie Archiwum Medycyny Wewnetrznej, 2014, Volume: 124, Issue:4

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2014
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
    American journal of clinical oncology, 2014, Volume: 37, Issue:4

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Genetic Markers; Humans; Nitriles; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles; Validation Studies as Topic

2014
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2014
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
    Current oncology reports, 2015, Volume: 17, Issue:11

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Mammography; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Precision Medicine; Prognosis; Radiotherapy, Adjuvant; Tamoxifen; Triazoles

2015
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
    Bulletin du cancer, 2016, Volume: 103, Issue:3

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles

2016
Unravelling exemestane: From biology to clinical prospects.
    The Journal of steroid biochemistry and molecular biology, 2016, Volume: 163

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles

2016
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
    Breast (Edinburgh, Scotland), 2016, Volume: 28

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2016
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
    The breast journal, 2017, Volume: 23, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles

2017
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
    Georgian medical news, 2017, Issue:262

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2017
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
    Oncotarget, 2017, Jul-18, Volume: 8, Issue:29

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2017
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 79

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Substitution; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2017
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
    Revista da Associacao Medica Brasileira (1992), 2017, Volume: 63, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles

2017
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
    Medicine, 2017, Volume: 96, Issue:33

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles

2017
Personalized prevention in high risk individuals: Managing hormones and beyond.
    Breast (Edinburgh, Scotland), 2018, Volume: 39

    Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles

2018
Endocrine Therapy for Ductal Carcinoma In Situ (DCIS) of the Breast with Breast Conserving Surgery (BCS) and Radiotherapy (RT): a Meta-Analysis.
    Pathology oncology research : POR, 2020, Volume: 26, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Incidence; Mastectomy, Segmental; Neoplasm Recurrence, Local; Radiotherapy; Tamoxifen

2020
Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis.
    Medicine, 2020, Volume: 99, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Humans; Letrozole; Lipids; Network Meta-Analysis; Research Design; Tamoxifen; Toremifene

2020
[Endocrine adjuvant treatment specific features for young breast cancer women].
    Bulletin du cancer, 2019, Volume: 106, Issue:12S1

    Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate

2019
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer : Statement from the DEGRO working group prostate cancer.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:7

    Topics: Adenocarcinoma; Anastrozole; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Dizziness; Dose Fractionation, Radiation; Drug Administration Schedule; Estrogen Receptor Modulators; Flushing; Gynecomastia; Humans; Male; Mastodynia; Meta-Analysis as Topic; Neoplasms, Hormone-Dependent; Nitriles; Off-Label Use; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tamoxifen; Tosyl Compounds

2020
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
    European journal of clinical investigation, 2021, Volume: 51, Issue:7

    Topics: Aminopyridines; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Letrozole; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trastuzumab

2021
Preventing Breast Cancer Through Identification and Pharmacologic Management of High-Risk Patients.
    Mayo Clinic proceedings, 2021, Volume: 96, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Curriculum; Decision Making, Shared; Education, Medical, Continuing; Estrogen Antagonists; Female; Health Personnel; Humans; Male; Middle Aged; Preventive Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; United States

2021
Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:4

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Hormones; Humans; Quality of Life; Tamoxifen

2023

Trials

133 trial(s) available for anastrozole and tamoxifen

ArticleYear
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles

1996
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
    British journal of cancer, 1999, Volume: 79, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

1999
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles

2000
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Nov-15, Volume: 18, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2000
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Nov-15, Volume: 18, Issue:22

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2000
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:5

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles

2001
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
    British journal of cancer, 2001, Aug-03, Volume: 85, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Safety; Tamoxifen; Treatment Outcome; Triazoles

2001
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
    Cancer, 2001, Nov-01, Volume: 92, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Hemorrhage; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Thromboembolism; Treatment Outcome; Triazoles

2001
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles

2002
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:15

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Nitriles; Patient Selection; Postmenopause; Surveys and Questionnaires; Tamoxifen; Triazoles

2002
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Clinical breast cancer, 2003, Volume: 4 Suppl 1

    Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States

2003
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
    American journal of clinical oncology, 2003, Volume: 26, Issue:3

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Remission Induction; Survival Analysis; Tamoxifen; Triazoles

2003
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:12

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2003
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:1

    Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles

2003
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
    Cancer, 2003, Nov-01, Volume: 98, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2003
Advanced breast cancer updates on anastrozole versus tamoxifen.
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:3-5

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles

2003
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:3-5

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2003
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
    BJOG : an international journal of obstetrics and gynaecology, 2003, Volume: 110, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2003
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
    Psycho-oncology, 2004, Volume: 13, Issue:1

    Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cognition Disorders; Depression; England; Estrogens; Female; Humans; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Nitriles; Personality Inventory; Pilot Projects; Reaction Time; Self-Assessment; Tamoxifen; Triazoles; Verbal Learning

2004
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
    British journal of cancer, 2004, Feb-09, Volume: 90, Issue:3

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Female; Goserelin; Humans; Injections, Subcutaneous; Middle Aged; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles

2004
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and
    Breast cancer research and treatment, 2004, Volume: 85, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Survival Rate; Switzerland; Tamoxifen; Triazoles

2004
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
    Cancer, 2004, Aug-15, Volume: 101, Issue:4

    Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Risk Factors; Tamoxifen; Triazoles; United Kingdom; United States

2004
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Cancer, 2004, Oct-01, Volume: 101, Issue:7

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles

2004
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
    Anti-cancer drugs, 2004, Volume: 15, Issue:8

    Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, Statistical; Demography; Dyspareunia; Female; Hot Flashes; Humans; Letrozole; Logistic Models; Memory Disorders; Menopause; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Patient Selection; Prospective Studies; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles; Urination Disorders; Vaginal Diseases; Withholding Treatment

2004
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
    Human reproduction (Oxford, England), 2005, Volume: 20, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Endometrium; Female; Humans; Hysteroscopy; Nitriles; Sensitivity and Specificity; Tamoxifen; Triazoles; Ultrasonography

2005
Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
    American journal of obstetrics and gynecology, 2004, Volume: 191, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Endometrium; Female; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Nitriles; Postmenopause; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2004
Biomarker investigations from the ATAC trial: the role of TA01.
    Breast cancer research and treatment, 2004, Volume: 87 Suppl 1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Oligonucleotide Array Sequence Analysis; Patient Care Planning; Prognosis; Tamoxifen; Triazoles

2004
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-01, Volume: 23, Issue:4

    Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Tamoxifen; Testosterone; Tosyl Compounds; Triazoles

2005
Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
    Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:1

    Topics: Aged; Aged, 80 and over; Anastrozole; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Diseases; Double-Blind Method; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Placebos; Prostatic Neoplasms; Tamoxifen; Testosterone; Tosyl Compounds; Treatment Outcome; Triazoles

2005
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 2

    Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles

2005
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-10, Volume: 23, Issue:11

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Triazoles

2005
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Female; Humans; Japan; Lipids; Lipoprotein Lipase; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2005
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
    Ginecologia y obstetricia de Mexico, 2004, Volume: 72

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles

2004
Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:3

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid

2005
Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:4

    Topics: Aged; Aged, 80 and over; Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Interactions; Gynecomastia; Humans; Male; Middle Aged; Nitriles; Pain; Prostatic Neoplasms; Tamoxifen; Tosyl Compounds; Triazoles

2005
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Odds Ratio; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2005
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Survival Analysis; Tamoxifen; Triazoles

2005
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers; Bone Resorption; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Humans; Lipids; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2005
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
    Nature clinical practice. Oncology, 2005, Volume: 2, Issue:10

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptor, ErbB-2; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2005
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
    Human reproduction (Oxford, England), 2006, Volume: 21, Issue:2

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Polyps; Risk Factors; Tamoxifen; Triazoles

2006
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-20, Volume: 23, Issue:30

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2005
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Humans; In Situ Nick-End Labeling; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Tamoxifen; Triazoles

2006
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-01, Volume: 12, Issue:3 Pt 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2006
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Feb-15, Volume: 12, Issue:4

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dilatation and Curettage; Endometrium; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography; Uterine Hemorrhage

2006
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
    Cancer, 2006, May-15, Volume: 106, Issue:10

    Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Logistic Models; Mastectomy; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Preoperative Care; Receptors, Estrogen; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2006
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2006
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2006, Volume: 21, Issue:8

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Fractures, Bone; Hip; Humans; Lumbar Vertebrae; Middle Aged; Nitriles; Postmenopause; Radiography; Risk; Tamoxifen; Triazoles

2006
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
    The Lancet. Oncology, 2006, Volume: 7, Issue:8

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles

2006
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
    Breast cancer research and treatment, 2006, Volume: 100, Issue:3

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Follow-Up Studies; Health Status; Humans; Nitriles; Odds Ratio; Patient Dropouts; Postmenopause; Quality of Life; Risk Assessment; Surveys and Questionnaires; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2006
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7

    Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid

2007
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
    International journal of radiation oncology, biology, physics, 2007, Jun-01, Volume: 68, Issue:2

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Radiotherapy Dosage; Survival Rate; Tamoxifen; Triazoles

2007
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
    Breast (Edinburgh, Scotland), 2007, Volume: 16, Issue:5

    Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-20, Volume: 25, Issue:15

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles

2007
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-01, Volume: 25, Issue:19

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Secondary Prevention; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2007
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
    British journal of cancer, 2007, Jul-16, Volume: 97, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom

2007
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
    Breast cancer research : BCR, 2007, Volume: 9, Issue:4

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles

2007
A decade of letrozole: FACE.
    Breast cancer research and treatment, 2007, Volume: 105 Suppl 1

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles

2007
Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:2

    Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Prospective Studies; Survivors; Tamoxifen; Treatment Outcome; Triazoles

2008
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:8

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2007
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
    Journal of the National Cancer Institute, 2007, Dec-19, Volume: 99, Issue:24

    Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Research Design; Tamoxifen; Treatment Outcome; Triazoles

2007
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:6

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles

2008
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
    The Lancet. Oncology, 2008, Volume: 9, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles

2008
ERBB2 status and outcome of endocrine treatment.
    The Lancet. Oncology, 2008, Volume: 9, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Female; Humans; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles

2008
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Tissue Array Analysis; Treatment Outcome; Triazoles

2008
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Invasiveness; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome; Triazoles

2008
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-01, Volume: 26, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2008
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, May-01, Volume: 14, Issue:9

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1

2008
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
    Breast (Edinburgh, Scotland), 2008, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography

2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    The Lancet. Oncology, 2008, Volume: 9, Issue:9

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid

2008
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
    Health expectations : an international journal of public participation in health care and health policy, 2008, Volume: 11, Issue:3

    Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Decision Support Techniques; Feedback; Female; Health Knowledge, Attitudes, Practice; Humans; Informed Consent; Middle Aged; Nitriles; Patient Education as Topic; Patient Selection; Pilot Projects; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Teaching Materials; Triazoles

2008
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
    Breast cancer research and treatment, 2009, Volume: 117, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; United Kingdom

2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    The New England journal of medicine, 2009, Feb-12, Volume: 360, Issue:7

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Estrogen Antagonists; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Premenopause; Receptors, Estrogen; Tamoxifen; Triazoles; Zoledronic Acid

2009
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
    Breast (Edinburgh, Scotland), 2009, Volume: 18, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2009
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Triazoles

2009
Comparison of the effect of the aromatase inhibitor, anastrazole, to the antioestrogen, tamoxifen citrate, on canine prostate and semen.
    Reproduction in domestic animals = Zuchthygiene, 2009, Volume: 44 Suppl 2

    Topics: Anastrozole; Animals; Aromatase Inhibitors; Dog Diseases; Dogs; Estrogen Antagonists; Male; Nitriles; Prostate; Prostatic Hyperplasia; Semen; Tamoxifen; Triazoles

2009
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Tegafur; Triazoles; Uracil

2009
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-15, Volume: 15, Issue:22

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Cytochrome P-450 CYP2D6; Disease-Free Survival; Female; Genotype; Humans; Nitriles; Pharmacogenetics; Precancerous Conditions; Risk; Tamoxifen; Treatment Outcome; Triazoles

2009
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    Breast cancer research and treatment, 2010, Volume: 119, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2010
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-10, Volume: 28, Issue:11

    Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genetic Testing; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles

2010
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
    Onkologie, 2010, Volume: 33, Issue:4

    Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Humans; Incidence; Middle Aged; Models, Economic; Nitriles; Tamoxifen; Triazoles

2010
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
    Breast cancer research and treatment, 2010, Volume: 121, Issue:2

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Triazoles

2010
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
    Current oncology reports, 2010, Volume: 12, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles; Zoledronic Acid

2010
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-20, Volume: 28, Issue:21

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles

2010
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2010, Volume: 30, Issue:6

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2010
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
    Breast cancer research and treatment, 2011, Volume: 125, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Endocrine System; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles

2011
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
    Menopause (New York, N.Y.), 2011, Volume: 18, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Quality of Life; Sexual Dysfunction, Physiological; Tamoxifen; Treatment Outcome; Triazoles; Uterus

2011
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Nitriles; Prospective Studies; Receptors, Progesterone; Tamoxifen; Triazoles

2011
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Female; Hip; Humans; Lumbar Vertebrae; Nitriles; Tamoxifen; Time; Triazoles

2011
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:12

    Topics: Administration, Oral; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2010
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides

2011
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
    Breast cancer research and treatment, 2011, Volume: 127, Issue:1

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles

2011
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Oncology, 2010, Volume: 79, Issue:5-6

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2010
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Nitriles; Premenopause; Prospective Studies; Recurrence; Retrospective Studies; Risk; Tamoxifen; Treatment Outcome; Triazoles

2011
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:7

    Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid

2011
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-10, Volume: 29, Issue:32

    Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Retrospective Studies; Risk; Tamoxifen; Triazoles

2011
Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.
    Cancer science, 2012, Volume: 103, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Nitriles; Postoperative Period; Tamoxifen; Triazoles

2012
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
    Genetic epidemiology, 2012, Volume: 36, Issue:1

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles

2012
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
    Breast cancer research and treatment, 2012, Volume: 133, Issue:1

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles

2012
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:4

    Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles

2012
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-01, Volume: 30, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Austria; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles

2012
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
    Breast cancer research : BCR, 2012, Apr-04, Volume: 14, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D1; Female; Follow-Up Studies; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles

2012
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
    Cancer, 2013, Feb-15, Volume: 119, Issue:4

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Goserelin; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2013
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:7

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2013
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
    Oncology reports, 2013, Volume: 29, Issue:5

    Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles

2013
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8

    Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Estradiol; Female; Humans; Middle Aged; Nitriles; Ovary; Primary Ovarian Insufficiency; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles; Uterine Hemorrhage

2013
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
    The Lancet. Oncology, 2013, Volume: 14, Issue:11

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles

2013
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
    BMC cancer, 2013, Sep-18, Volume: 13

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles

2013
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:5

    Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Early Detection of Cancer; Female; Follow-Up Studies; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mucin-1; Nitriles; Pilot Projects; Single-Blind Method; Tamoxifen; Treatment Outcome; Triazoles

2014
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
    Cancer science, 2014, Volume: 105, Issue:9

    Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Liver; Middle Aged; Nitriles; Prospective Studies; Tamoxifen; Treatment Failure; Triazoles

2014
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
    Breast cancer research and treatment, 2014, Volume: 148, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Triazoles

2014
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-10, Volume: 33, Issue:8

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Data Interpretation, Statistical; Female; Follow-Up Studies; Hormones; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Regression Analysis; Risk; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2015
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid

2015
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
    Future oncology (London, England), 2015, Volume: 11, Issue:2

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles

2015
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
    Breast cancer research and treatment, 2015, Volume: 152, Issue:3

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles

2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
    Lancet (London, England), 2016, Feb-27, Volume: 387, Issue:10021

    Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles

2016
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Lancet (London, England), 2016, Feb-27, Volume: 387, Issue:10021

    Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Method; Embolism; Female; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Thrombosis; Triazoles

2016
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Lancet (London, England), 2016, Feb-27, Volume: 387, Issue:10021

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Quality of Life; Tamoxifen; Triazoles

2016
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
    Annals of surgical oncology, 2017, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult

2017
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:11

    Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Mastectomy; Maximum Tolerated Dose; Middle Aged; Netherlands; Nitriles; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2017
Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 02-01, Volume: 29, Issue:2

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Double-Blind Method; Female; Humans; Medication Adherence; Middle Aged; Tamoxifen

2018
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    JAMA oncology, 2018, Apr-01, Volume: 4, Issue:4

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Retrospective Studies; Tamoxifen; Transcriptome; Treatment Outcome

2018
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:4

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen

2018
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 07-01, Volume: 36, Issue:19

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Reproducibility of Results; Risk; Tamoxifen

2018
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label,
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 103

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fulvestrant; Goserelin; Humans; Neoplasm Metastasis; Premenopause; Tamoxifen

2018
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
    Advances in therapy, 2018, Volume: 35, Issue:11

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Letrozole; Male; Middle Aged; Neoplasm Staging; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Tamoxifen; Treatment Outcome

2018
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
    BMJ open, 2018, 12-22, Volume: 8, Issue:12

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Cross-Over Studies; Disease-Free Survival; Feasibility Studies; Female; Genetic Predisposition to Disease; Goserelin; Heterozygote; Humans; Mutation; Northern Ireland; Patient Acceptance of Health Care; Patient Selection; Premenopause; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome; Ubiquitin-Protein Ligases

2018
Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.
    International journal of cancer, 2019, 07-01, Volume: 145, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovary; Postmenopause; Proportional Hazards Models; Survival Rate; Tamoxifen

2019
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
    International journal of cancer, 2019, 09-01, Volume: 145, Issue:5

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen

2019
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
    The British journal of surgery, 2021, 04-05, Volume: 108, Issue:3

    Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Profiling; Humans; Lymph Nodes; Mastectomy, Segmental; Neoplasm Grading; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen

2021
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Fractures, Bone; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen

2021
Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 164

    Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2; Retrospective Studies; Tamoxifen

2022
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 06-20, Volume: 41, Issue:18

    Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Prospective Studies; Tamoxifen; Triazoles

2023
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
    Annals of surgical oncology, 2023, Volume: 30, Issue:13

    Topics: Anastrozole; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ethnicity; Female; Humans; Tamoxifen

2023

Other Studies

268 other study(ies) available for anastrozole and tamoxifen

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
    Journal of medicinal chemistry, 2009, Dec-10, Volume: 52, Issue:23

    Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
    Bioorganic & medicinal chemistry letters, 2015, Apr-01, Volume: 25, Issue:7

    Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics

2015
Aromatase inhibitors in metastatic breast cancer.
    Seminars in oncology, 1996, Volume: 23, Issue:4 Suppl 9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles

1996
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
    The Nurse practitioner, 1997, Volume: 22, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles

1997
Fetal death in mice lacking 5alpha-reductase type 1 caused by estrogen excess.
    Molecular endocrinology (Baltimore, Md.), 1997, Volume: 11, Issue:7

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Anastrozole; Androstenedione; Animals; Biological Assay; Decidua; Dose-Response Relationship, Drug; Embryonic and Fetal Development; Estrogen Antagonists; Estrogens; Female; Fetal Death; Gene Expression Regulation, Enzymologic; In Situ Hybridization; Litter Size; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitriles; Placenta; RNA, Messenger; Steroids; Tamoxifen; Triazoles; Uterus

1997
Predictors of response to second-line endocrine therapy for breast cancer.
    Breast cancer research and treatment, 1997, Volume: 45, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gonanes; Goserelin; Humans; Megestrol Acetate; Middle Aged; Nitriles; Ovariectomy; Predictive Value of Tests; Remission Induction; Tamoxifen; Triazoles

1997
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:3 Suppl 5

    Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; Tumor Cells, Cultured; Uterus

1998
The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
    Breast cancer research and treatment, 1998, Volume: 50, Issue:1

    Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured

1998
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
    Breast cancer research and treatment, 1999, Volume: 55, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evaluation Studies as Topic; Female; Hormone Replacement Therapy; Humans; Megestrol Acetate; Menopause; Middle Aged; Nitriles; Pilot Projects; Quality of Life; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles

1999
The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Breast cancer research and treatment, 1999, Volume: 57, Issue:2

    Topics: Analysis of Variance; Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Tamoxifen; Time Factors; Triazoles; Tumor Cells, Cultured

1999
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
    Annals of surgical oncology, 1999, Volume: 6, Issue:8 Suppl

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Tolerance; Female; Humans; Megestrol Acetate; Nitriles; Safety; Tamoxifen; Triazoles

1999
Future directions in endocrine treatment of advanced breast cancer.
    Annals of surgical oncology, 1999, Volume: 6, Issue:8 Suppl

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Megestrol Acetate; Nitriles; Tamoxifen; Triazoles

1999
Endocrine options for breast cancer treatment: looking beyond tamoxifen.
    Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Goserelin; Humans; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles

2000
Clinical trials in cancer: what makes for a successful study?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Drug Industry; Female; Humans; Interinstitutional Relations; Mastectomy; Medical Audit; Motivation; Multicenter Studies as Topic; Nitriles; Patient Selection; Patients; Physician-Patient Relations; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles

2000
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
    The oncologist, 2001, Volume: 6, Issue:1

    Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration

2001
The Twenty-third Annual San Antonio Breast Cancer Symposium.
    Current medical research and opinion, 2001, Volume: 16, Issue:4

    Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2001
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2001
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2001
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2001
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2001
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2001
Aromatase inhibitors and inactivators in breast cancer.
    BMJ (Clinical research ed.), 2001, Oct-20, Volume: 323, Issue:7318

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2001
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
    Cancer research, 2001, Dec-01, Volume: 61, Issue:23

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplification; Humans; Immunohistochemistry; Ki-67 Antigen; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles

2001
World's largest breast cancer treatment trial supports anastrozole use.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2002
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
    The Journal of steroid biochemistry and molecular biology, 2001, Volume: 79, Issue:1-5

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles

2001
Hormones 'R' us.
    Clinical breast cancer, 2002, Volume: 2, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2002
New breast cancer drugs expand treatment options.
    Harvard women's health watch, 2002, Volume: 9, Issue:8

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2002
A better medication for treating breast cancer?
    The Johns Hopkins medical letter health after 50, 2002, Volume: 14, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles

2002
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
    Lancet (London, England), 2002, Jun-22, Volume: 359, Issue:9324

    Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles

2002
Estrogen as therapy for breast cancer.
    Breast cancer research : BCR, 2002, Volume: 4, Issue:4

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles

2002
Promising results for Arimidex and Femara.
    Expert review of anticancer therapy, 2001, Volume: 1, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2001
Stick with tried-and-true breast cancer treatment.
    Health news (Waltham, Mass.), 2002, Volume: 8, Issue:7

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles

2002
Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome.
    Journal of pediatric endocrinology & metabolism : JPEM, 2002, Volume: 15 Suppl 3

    Topics: Anastrozole; Aromatase Inhibitors; Child; Enzyme Inhibitors; Estrogen Antagonists; Female; Fibrous Dysplasia, Polyostotic; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menarche; Nitriles; Puberty, Precocious; Tamoxifen; Triazoles

2002
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles

2002
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
    MMW Fortschritte der Medizin, 2002, Sep-19, Volume: 144, Issue:38

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Treatment Outcome; Triazoles

2002
Anastrozole versus progestins/tamoxifen.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Forecasting; Humans; Multicenter Studies as Topic; Nitriles; Progestins; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles

2002
Selective oestrogen receptor downregulator.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 6

    Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2002
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
    Cancer, 2002, Dec-01, Volume: 95, Issue:11

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Multicenter Studies as Topic; Nitriles; Reproducibility of Results; Research Design; Retrospective Studies; Survival; Tamoxifen; Triazoles

2002
Effects of anastrozole on lipid metabolism compared with tamoxifen in rats.
    Breast cancer research and treatment, 2002, Volume: 76, Issue:2

    Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Cholesterol; Drug Combinations; Enzyme Inhibitors; Female; Lipoprotein Lipase; Nitriles; Rats; Tamoxifen; Triazoles; Triglycerides

2002
Current role of endocrine therapy in the management of breast cancer.
    Breast cancer (Tokyo, Japan), 2002, Volume: 9, Issue:4

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2002
Has tamoxifen had its day?
    Breast cancer research : BCR, 2002, Volume: 4, Issue:6

    Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles

2002
A new day dawns: women without oestrogen or is a balance best?
    Breast cancer research : BCR, 2002, Volume: 4, Issue:6

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Tamoxifen; Triazoles

2002
Advances in breast oncology: the 2002 ASCO meeting.
    Current medical research and opinion, 2002, Volume: 18, Issue:7

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles

2002
New treatment option for postmenopausal women with early breast cancer.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:6

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2002
[Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].
    MMW Fortschritte der Medizin, 2003, Jan-23, Volume: 145, Issue:3-4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mammography; Mass Screening; Nitriles; Quality Assurance, Health Care; Tamoxifen; Triazoles

2003
Update on ATAC.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:3

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles

2003
Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
    The Medical letter on drugs and therapeutics, 2003, Mar-17, Volume: 45, Issue:1152

    Topics: Anastrozole; Asthenia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Estrogen Antagonists; Fees, Pharmaceutical; Female; Headache; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2003
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
    American journal of clinical oncology, 2003, Volume: 26, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Quality of Life; Tamoxifen; Triazoles

2003
ATAC trial: reporting interim results is not helpful.
    BMJ (Clinical research ed.), 2003, Jun-14, Volume: 326, Issue:7402

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles

2003
Breast cancer prevention.
    The British journal of general practice : the journal of the Royal College of General Practitioners, 2003, Volume: 53, Issue:487

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Utilization; Female; Humans; Nitriles; Tamoxifen; Triazoles

2003
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
    MMW Fortschritte der Medizin, 2003, Jun-12, Volume: 145, Issue:24

    Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles

2003
Examining quality of life issues in relation to endocrine therapy for breast cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Making; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Quality of Life; Tamoxifen; Triazoles

2003
Future directions in the endocrine therapy of breast cancer.
    Breast cancer research and treatment, 2003, Volume: 80 Suppl 1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine System; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles

2003
Adjuvant aromatase inhibitors: are we there yet?
    Cancer, 2003, Nov-01, Volume: 98, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles

2003
ATAC trial did not report interim results.
    BMJ (Clinical research ed.), 2003, Nov-01, Volume: 327, Issue:7422

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles

2003
The effects of hormone therapy on cognition in breast cancer.
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:3-5

    Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition; Cognition Disorders; Enzyme Inhibitors; Female; Humans; Memory; Middle Aged; Nitriles; Pilot Projects; Psychometrics; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2003
Hormonal therapy: introduction.
    Breast (Edinburgh, Scotland), 2003, Volume: 12 Suppl 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Prognosis; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom

2003
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
    Clinical therapeutics, 2003, Volume: 25, Issue:11

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Health Care Costs; Health Services; Humans; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles

2003
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 2

    Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles

2004
Prevention strategies with aromatase inhibitors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Enzyme Inhibitors; Female; Humans; Isoenzymes; Membrane Proteins; Models, Biological; Neoplasms; Nitriles; Placebos; Postmenopause; Prostaglandin-Endoperoxide Synthases; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles

2004
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
    Journal of surgical oncology, 2004, Volume: 85, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Bridged-Ring Compounds; Feasibility Studies; Female; Goserelin; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Nitriles; Pilot Projects; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Triazoles

2004
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
    MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50

    Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms

2003
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
    MMW Fortschritte der Medizin, 2003, Dec-11, Volume: 145, Issue:50

    Topics: Age Factors; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Life Style; Mammography; Middle Aged; Nitriles; Quality of Life; Risk Assessment; Risk Factors; Tamoxifen; Triazoles

2003
[The uterine sarcoma, a new risk identified for tamoxifen].
    Presse medicale (Paris, France : 1983), 2004, Mar-13, Volume: 33, Issue:5

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinosarcoma; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Metrorrhagia; Middle Aged; Neoplasms, Second Primary; Nitriles; Risk; Tamoxifen; Triazoles; Uterine Neoplasms

2004
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:7

    Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles

2004
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
    Acta radiologica (Stockholm, Sweden : 1987), 2004, Volume: 45, Issue:1

    Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid

2004
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Cancer, 2004, Sep-15, Volume: 101, Issue:6

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Middle Aged; Models, Theoretical; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles

2004
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-01, Volume: 22, Issue:21

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Quality of Life; Surveys and Questionnaires; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2004
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Clinical therapeutics, 2004, Volume: 26, Issue:9

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Italy; Letrozole; Markov Chains; Megestrol; Models, Economic; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2004
Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.
    British journal of cancer, 2005, Jan-31, Volume: 92, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogens; Female; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Nitriles; Pituitary Gland; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2005
How rapidly do oncologists respond to clinical trial data?
    The oncologist, 2005, Volume: 10, Issue:1

    Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Health Care Surveys; Humans; Medical Oncology; Middle Aged; Nitriles; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles

2005
Anastrozole data show continued delay in relapse, but no clear survival advantage.
    Journal of the National Cancer Institute, 2005, Jan-19, Volume: 97, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom

2005
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
    Bulletin of experimental biology and medicine, 2004, Volume: 138, Issue:5

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Nitriles; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Triazoles

2004
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
    MMW Fortschritte der Medizin, 2005, Mar-10, Volume: 147, Issue:10

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Germany; Humans; Mammography; Middle Aged; Multicenter Studies as Topic; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Risk; Risk Factors; Tamoxifen; Time Factors; Triazoles

2005
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
    MMW Fortschritte der Medizin, 2005, Mar-10, Volume: 147, Issue:10

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles

2005
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
    Molecular cancer research : MCR, 2005, Volume: 3, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Tamoxifen; Triazoles; Up-Regulation

2005
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles

2005
Aromatase inhibitors: cellular and molecular effects.
    The Journal of steroid biochemistry and molecular biology, 2005, Volume: 95, Issue:1-5

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles

2005
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
    The New England journal of medicine, 2005, Aug-11, Volume: 353, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diagnosis, Differential; Female; Humans; Mammography; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Receptors, Estrogen; Sentinel Lymph Node Biopsy; Tamoxifen; Triazoles

2005
Radiotherapeutic prophylaxis of gynecomastia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Anastrozole; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Gynecomastia; Humans; Male; Nitriles; Pain; Prostatic Neoplasms; Quality of Life; Tamoxifen; Tosyl Compounds; Triazoles

2005
Regression of tamoxifen-stimulated massive uterine fibroid after conversion to anastrozole.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2005, Volume: 25, Issue:6

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Female; Humans; Leiomyoma; Nitriles; Remission Induction; Retreatment; Tamoxifen; Triazoles; Ultrasonography; Uterine Neoplasms

2005
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
    The Journal of steroid biochemistry and molecular biology, 2005, Volume: 97, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Estrogen Antagonists; Humans; Inhibitory Concentration 50; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles

2005
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
    The New England journal of medicine, 2005, Nov-24, Volume: 353, Issue:21

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles

2005
Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Developing Countries; Disease-Free Survival; Drug Costs; Female; Humans; Nitriles; Tamoxifen; Triazoles

2005
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
    Archives of dermatology, 2006, Volume: 142, Issue:1

    Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Antagonists; Exanthema; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Skin; Tamoxifen; Triazoles

2006
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
    Health news (Waltham, Mass.), 2005, Volume: 11, Issue:12

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles

2005
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2005, Volume: 59 Suppl 2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2005
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
    Oncology research, 2006, Volume: 15, Issue:9

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles

2006
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:9

    Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2006
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
    MMW Fortschritte der Medizin, 2006, Mar-23, Volume: 148, Issue:12

    Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Humans; Mammography; Meta-Analysis as Topic; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk; Tamoxifen; Taxoids; Time Factors; Trastuzumab; Triazoles

2006
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
    Breast cancer research and treatment, 2006, Volume: 100, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Renal Dialysis; Tamoxifen; Triazoles

2006
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

    Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles

2006
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles

2006
Estrogen receptors: role in breast cancer.
    Critical reviews in clinical laboratory sciences, 2006, Volume: 43, Issue:4

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Letrozole; Models, Biological; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2006
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
    Current opinion in ophthalmology, 2006, Volume: 17, Issue:3

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2006
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
    Cancer, 2006, Aug-01, Volume: 107, Issue:3

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles

2006
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
    Breast cancer research and treatment, 2007, Volume: 101, Issue:3

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States

2007
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
    Anti-cancer drugs, 2006, Volume: 17, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Economics, Pharmaceutical; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Slovenia; Tamoxifen; Treatment Outcome; Triazoles

2006
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2006, Volume: 16 Suppl 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2006
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Nitriles; Postmenopause; Quality of Life; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles

2007
Clinically occult cutaneous metastases.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6

    Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing

2006
Impact of aromatase inhibitors on adhesion formation in a rat model.
    Fertility and sterility, 2007, Volume: 87, Issue:4

    Topics: Anastrozole; Animals; Aromatase Inhibitors; Cytokines; Disease Models, Animal; Female; Medroxyprogesterone Acetate; Nitriles; Postoperative Complications; Rats; Rats, Wistar; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Tissue Adhesions; Triazoles; Uterine Diseases; Uterus

2007
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Breast (Edinburgh, Scotland), 2007, Volume: 16, Issue:3

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles

2007
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1

    Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Nitriles; Remission Induction; Tamoxifen; Triazoles

2007
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Journal of the National Cancer Institute, 2007, Jan-17, Volume: 99, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Sample Size; Tamoxifen; Triazoles

2007
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone
    Breast cancer research and treatment, 2007, Volume: 106, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Health Services Research; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles; United Kingdom; United States

2007
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
    Breast cancer research and treatment, 2007, Volume: 106, Issue:2

    Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Lasers; Middle Aged; Nitriles; Ophthalmoscopy; Optic Disk; Selective Estrogen Receptor Modulators; Survival Rate; Survivors; Tamoxifen; Triazoles; Visual Acuity

2007
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
    Breast (Edinburgh, Scotland), 2007, Volume: 16, Issue:5

    Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles

2007
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
    Current medical research and opinion, 2007, Volume: 23, Issue:5

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colles' Fracture; Female; Fractures, Bone; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles; Wrist Injuries

2007
Optimal use of aromatase inhibitors: to lead or to follow?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-01, Volume: 25, Issue:19

    Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Tamoxifen; Treatment Outcome; Triazoles

2007
Bone density in breast cancer: when to intervene?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid

2007
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2008, Volume: 9, Issue:2

    Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United Kingdom

2008
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
    Anti-cancer drugs, 2007, Volume: 18, Issue:8

    Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Ovariectomy; Piperidines; Pyridines; S Phase; Tamoxifen; Triazoles

2007
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
    The Journal of rheumatology, 2007, Volume: 34, Issue:11

    Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Sjogren's Syndrome; Tamoxifen; Triazoles

2007
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2007, Volume: 85, Issue:3

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Middle Aged; Nitriles; Postmenopause; Radiotherapy Dosage; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles

2007
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
    International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles

2007
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
    Cancer, 2008, Feb-01, Volume: 112, Issue:3 Suppl

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles

2008
Extended adjuvant therapy for breast cancer--how much is enough?
    Journal of the National Cancer Institute, 2007, Dec-19, Volume: 99, Issue:24

    Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles

2007
Long-term outcomes of aromatase inhibition for breast cancer.
    The Lancet. Oncology, 2008, Volume: 9, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Time Factors; Triazoles

2008
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
    Anti-cancer drugs, 2008, Volume: 19 Suppl 2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles

2008
Inappropriate ATAC on tamoxifen.
    The Lancet. Oncology, 2008, Volume: 9, Issue:4

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Triazoles

2008
Inappropriate ATAC on tamoxifen.
    The Lancet. Oncology, 2008, Volume: 9, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2008
Retinal hemorrhages in anastrozole users.
    Optometry and vision science : official publication of the American Academy of Optometry, 2008, Volume: 85, Issue:5

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Middle Aged; Nitriles; Patient Selection; Retinal Hemorrhage; Retrospective Studies; Tamoxifen; Tomography, Optical Coherence; Triazoles

2008
MCF-7aro/ERE, a novel cell line for rapid screening of aromatase inhibitors, ERalpha ligands and ERRalpha ligands.
    Biochemical pharmacology, 2008, Jul-15, Volume: 76, Issue:2

    Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Cell Line, Tumor; Coumarins; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Fulvestrant; Genes, Reporter; Genistein; Humans; Letrozole; Ligands; Luciferases; Nitriles; Receptors, Estrogen; Response Elements; Tamoxifen; Thiazoles; Transfection; Triazoles

2008
Cutaneous vasculitis in breast cancer treated with chemotherapy.
    Clinical immunology (Orlando, Fla.), 2008, Volume: 129, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Female; Humans; Middle Aged; Nitriles; Paraneoplastic Syndromes; Skin Diseases, Vascular; Tamoxifen; Triazoles; Vasculitis

2008
[Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
    Magyar onkologia, 2008, Volume: 52, Issue:2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Time Factors; Triazoles

2008
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
    The Lancet. Oncology, 2008, Volume: 9, Issue:9

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthritis; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Interactions; Female; Humans; Joint Diseases; Likelihood Functions; Logistic Models; Middle Aged; Multivariate Analysis; Nitriles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles

2008
Vitreo-retinal traction and anastrozole use.
    Breast cancer research and treatment, 2009, Volume: 117, Issue:1

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fovea Centralis; Humans; Middle Aged; Nitriles; Tamoxifen; Tomography, Optical Coherence; Triazoles

2009
Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.
    Clinical breast cancer, 2008, Volume: 8, Issue:4

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Practice Guidelines as Topic; Tamoxifen; Triazoles

2008
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Journal of the National Cancer Institute, 2008, Sep-17, Volume: 100, Issue:18

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Female; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles

2008
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Journal of the National Cancer Institute, 2008, Sep-17, Volume: 100, Issue:18

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Decision Making; Disease-Free Survival; Estrogen Receptor Modulators; Female; Genotype; Humans; Markov Chains; Middle Aged; Nitriles; Patient Participation; Postmenopause; Tamoxifen; Triazoles

2008
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Journal of the National Cancer Institute, 2008, Oct-01, Volume: 100, Issue:19

    Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles

2008
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
    The Lancet. Oncology, 2008, Volume: 9, Issue:12

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neoplasms; Female; Hot Flashes; Humans; Joints; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Vasomotor System

2008
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
    American journal of obstetrics and gynecology, 2009, Volume: 200, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Retrospective Studies; Tamoxifen; Triazoles

2009
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
    Psycho-oncology, 2009, Volume: 18, Issue:8

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Female; Follow-Up Studies; Humans; Mental Recall; Middle Aged; Neoplasms, Hormone-Dependent; Neuropsychological Tests; Nitriles; Prospective Studies; Psychometrics; Reaction Time; Receptors, Estrogen; Tamoxifen; Triazoles

2009
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles

2009
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:2

    Topics: Adult; Aged; Anastrozole; Blood Platelets; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Platelet Count; Retrospective Studies; Tamoxifen; Triazoles

2010
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
    Breast (Edinburgh, Scotland), 2009, Volume: 18, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Nitriles; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles

2009
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5

    Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Female; Hormone Replacement Therapy; Humans; Lymphatic Metastasis; Nitriles; Pleural Neoplasms; Radiography; Recurrence; Skin Neoplasms; Tamoxifen; Tegafur; Time Factors; Triazoles; Uracil

2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid

2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid

2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Therapy, Combination; Female; Goserelin; Humans; Nitriles; Premenopause; Tamoxifen; Triazoles

2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid

2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    The New England journal of medicine, 2009, May-28, Volume: 360, Issue:22

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles; Zoledronic Acid

2009
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
    Critical reviews in oncology/hematology, 2009, Volume: 72, Issue:1

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles

2009
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
    Anticancer research, 2009, Volume: 29, Issue:6

    Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured

2009
NCCN Guideline update: Breast Cancer Version 1.2004.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2004, Volume: 2, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles

2004
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
    Drug metabolism reviews, 2010, Volume: 42, Issue:1

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles

2010
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
    The Journal of steroid biochemistry and molecular biology, 2010, Feb-28, Volume: 118, Issue:4-5

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2010
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
    Breast cancer research and treatment, 2010, Volume: 123, Issue:2

    Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays

2010
Role of testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate treatment in idiopathic oligoasthenoteratozoospermic men.
    Urologia internationalis, 2009, Volume: 83, Issue:4

    Topics: Adult; Anastrozole; Aromatase Inhibitors; Estradiol; Humans; Male; Nitriles; Oligospermia; Predictive Value of Tests; Sperm Motility; Spermatozoa; Tamoxifen; Testosterone; Triazoles

2009
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
    Applied immunohistochemistry & molecular morphology : AIMM, 2010, Volume: 18, Issue:3

    Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection of Cancer; Female; Gonadal Steroid Hormones; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles

2010
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
    Journal of clinical and experimental neuropsychology, 2010, Volume: 32, Issue:8

    Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists; Fatigue; Female; Humans; Memory Disorders; Middle Aged; Mood Disorders; Neuropsychological Tests; Nitriles; Postmenopause; Statistics, Nonparametric; Surveys and Questionnaires; Tamoxifen; Triazoles

2010
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-20, Volume: 28, Issue:21

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Menopause; Nitriles; Obesity; Tamoxifen; Triazoles

2010
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
    Onkologie, 2010, Volume: 33, Issue:7

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid

2010
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
    Cancer investigation, 2010, Volume: 28 Suppl 1

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Research Design; Tamoxifen; Treatment Outcome; Triazoles

2010
Cognitive changes associated with endocrine therapy for breast cancer.
    Maturitas, 2010, Volume: 67, Issue:3

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health

2010
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
    Analytical and bioanalytical chemistry, 2010, Volume: 398, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Letrozole; Middle Aged; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Tandem Mass Spectrometry; Triazoles

2010
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:16

    Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Middle Aged; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles

2010
What is the value of the 21 gene recurrence score in HER2-negative patients?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Kaplan-Meier Estimate; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Neoplasm; Tamoxifen; Triazoles

2010
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles

2010
10 years of ATAC: one question answered, many others unresolved.
    The Lancet. Oncology, 2010, Volume: 11, Issue:12

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Nitriles; Tamoxifen; Triazoles

2010
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles

2010
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8

    Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles

2011
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
    Anticancer research, 2011, Volume: 31, Issue:1

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles

2011
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Proto-Oncogene Proteins c-myc; RNA Interference; Tamoxifen; Treatment Outcome; Triazoles

2011
10-year analysis of the ATAC trial: wrong conclusion?
    The Lancet. Oncology, 2011, Volume: 12, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles

2011
Predictive algorithms for adjuvant therapy: TransATAC.
    Steroids, 2011, Volume: 76, Issue:8

    Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2011
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
    Fertility and sterility, 2011, Volume: 95, Issue:7

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Female; Humans; Middle Aged; Nitriles; Ovarian Hyperstimulation Syndrome; Ovariectomy; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles

2011
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Steryl-Sulfatase; Tamoxifen; Triazoles

2011
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Surgical Procedures, Operative; Tamoxifen; Triazoles; Wounds and Injuries

2012
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
    Annals of the Royal College of Surgeons of England, 2011, Volume: 93, Issue:4

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles

2011
Embracing the complexity of comorbidity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-10, Volume: 29, Issue:32

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles

2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Nitriles; Outcome Assessment, Health Care; Postmenopause; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2011
The breast cancer chemoprevention debate.
    Journal of the National Cancer Institute, 2011, Nov-16, Volume: 103, Issue:22

    Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2011
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
    Annals of surgical oncology, 2012, Volume: 19, Issue:4

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles

2012
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
    Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles

2011
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2011, Volume: 14, Issue:8

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2D6; Decision Support Techniques; Economics, Pharmaceutical; Female; Genotype; Humans; Markov Chains; Nitriles; Pharmacogenetics; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles; United Kingdom

2011
Aromatase inhibitors in premenopausal breast cancer.
    The Lancet. Oncology, 2012, Volume: 13, Issue:4

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles

2012
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-01, Volume: 30, Issue:7

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles

2012
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Journal of the National Cancer Institute, 2012, Mar-21, Volume: 104, Issue:6

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Female; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Risk Factors; Tamoxifen; Triazoles; United Kingdom

2012
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
    Breast cancer research and treatment, 2012, Volume: 134, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles; Weight Gain

2012
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
    BMJ case reports, 2010, Nov-02, Volume: 2010

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Nitriles; Osteoarthritis; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2010
Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:3

    Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Combined Modality Therapy; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Rats; Rats, Wistar; Statistics, Nonparametric; Tamoxifen; Triazoles

2013
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Practice Guidelines as Topic; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Risk Assessment; Tamoxifen; Treatment Outcome; Triazoles

2013
Development and validation of a simple and sensitive high performance liquid chromatographic method for the simultaneous determination of anastrozole, bicalutamide, tamoxifen, and their synthetic impurities.
    Talanta, 2012, Nov-15, Volume: 101

    Topics: Analysis of Variance; Anastrozole; Anilides; Calibration; Chromatography, High Pressure Liquid; Limit of Detection; Nitriles; Reproducibility of Results; Tamoxifen; Tosyl Compounds; Triazoles

2012
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles

2013
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
    Journal of alternative and complementary medicine (New York, N.Y.), 2013, Volume: 19, Issue:8

    Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nitriles; Prospective Studies; Republic of Korea; Severity of Illness Index; Tamoxifen; Treatment Outcome; Triazoles

2013
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
    Breast (Edinburgh, Scotland), 2013, Volume: 22, Issue:4

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Time Factors; Treatment Outcome; Triazoles

2013
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Aug-01, Volume: 31, Issue:22

    Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk; Tamoxifen; Triazoles

2013
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
    Breast cancer research and treatment, 2013, Volume: 140, Issue:2

    Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transcription Factors; Treatment Outcome; Triazoles

2013
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
    British journal of cancer, 2013, Dec-10, Volume: 109, Issue:12

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Differentiation; Cell Growth Processes; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Signal Transduction; Tamoxifen; Treatment Outcome; Triazoles

2013
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Hydroxyprostaglandin Dehydrogenases; Letrozole; Middle Aged; Nitriles; Receptors, Progesterone; ROC Curve; Tamoxifen; Treatment Outcome; Triazoles

2013
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
    PharmacoEconomics, 2014, Volume: 32, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Models, Economic; Models, Structural; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Triazoles; Uncertainty

2014
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:2

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Risk; Risk Assessment; Tamoxifen; Transcriptome; Treatment Outcome; Triazoles

2014
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Practice Guidelines as Topic; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Tumor Burden

2014
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 2015, Volume: 13, Issue:2

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Tamoxifen; Triazoles

2015
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
    Annals of surgical oncology, 2014, Volume: 21, Issue:5

    Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles

2014
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles

2014
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
    BMJ open, 2014, Jun-12, Volume: 4, Issue:6

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Qualitative Research; Quality of Life; Tamoxifen; Triazoles

2014
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
    Breast cancer research and treatment, 2014, Volume: 147, Issue:3

    Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Androgen; Tamoxifen; Triazoles

2014
Case report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid gland.
    BMC cancer, 2014, Sep-23, Volume: 14

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Ductal; Disease-Free Survival; Female; Humans; Neoplasm Metastasis; Nitriles; Parotid Neoplasms; Tamoxifen; Treatment Outcome; Triazoles

2014
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Prospective Studies; Tamoxifen; Triazoles

2014
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
    Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:1

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles

2015
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
    Gynecologic and obstetric investigation, 2015, Volume: 80, Issue:1

    Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles

2015
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Annals of surgical oncology, 2015, Volume: 22, Issue:12

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Triazoles

2015
Breast cancer risk reduction therapy: the low-hanging fruit.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles

2015
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Triazoles

2015
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
    Journal of affective disorders, 2015, Aug-15, Volume: 182

    Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles

2015
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:9

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Female; Geriatrics; Humans; Letrozole; Mastectomy; Nitriles; Oncology Nursing; Patient Preference; Receptors, Estrogen; Surgeons; Surveys and Questionnaires; Tamoxifen; Triazoles; United Kingdom

2015
Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.
    Acta obstetricia et gynecologica Scandinavica, 2015, Volume: 94, Issue:11

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Goserelin; Granulosa Cell Tumor; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Ovarian Neoplasms; Ovariectomy; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Salpingectomy; Tamoxifen; Triazoles

2015
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
    Breast (Edinburgh, Scotland), 2015, Volume: 24 Suppl 2

    Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Letrozole; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles

2015
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
    Breast (Edinburgh, Scotland), 2015, Volume: 24 Suppl 2

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Patient Selection; Prognosis; Tamoxifen; Time Factors; Triazoles

2015
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
    Chemotherapy, 2016, Volume: 61, Issue:2

    Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Leptin; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles

2016
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
    Nature communications, 2016, Feb-09, Volume: 7

    Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles

2016
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; Health Status Indicators; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles

2016
Aromatase inhibitors decrease radiation-induced lung fibrosis: Results of an experimental study.
    Breast (Edinburgh, Scotland), 2016, Volume: 28

    Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Chemotherapy, Adjuvant; Female; Letrozole; Nitriles; Pulmonary Fibrosis; Radiation Injuries, Experimental; Radiotherapy; Rats; Rats, Wistar; Tamoxifen; Triazoles

2016
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:11

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Likelihood Functions; Lymph Nodes; Lymphatic Metastasis; Nitriles; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Tamoxifen; Triazoles; Tumor Burden

2016
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Breast Neoplasms; Disease-Free Survival; Female; Homeodomain Proteins; Humans; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Interleukin-17; Receptors, Progesterone; Tamoxifen; Triazoles

2016
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
    Menopause (New York, N.Y.), 2016, Volume: 23, Issue:10

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Breast Neoplasms; Female; Humans; Lasers, Gas; Middle Aged; Nitriles; Retrospective Studies; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles; Vagina; Vaginal Diseases; Vulva

2016
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-01, Volume: 35, Issue:10

    Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Leuprolide; Maintenance Chemotherapy; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Nitriles; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Survival Rate; Tamoxifen; Triazoles; Watchful Waiting; Young Adult

2017
High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
    Journal of women's health (2002), 2017, Volume: 26, Issue:6

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Ethnicity; Female; Humans; Insurance, Health; Medicaid; Medically Uninsured; Neoplasm Staging; Nitriles; Safety-net Providers; Tamoxifen; Treatment Outcome; Triazoles; United States

2017
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
    Medical hypotheses, 2017, Volume: 101

    Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A

2017
MAMMARY GLAND ADENOCARCINOMA IN A MALE BORNEAN ORANGUTAN (PONGO PYGMAEUS).
    Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 2017, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Ape Diseases; Male; Mammary Neoplasms, Animal; Neoplasms, Hormone-Dependent; Nitriles; Pongo pygmaeus; Tamoxifen; Triazoles

2017
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 08-10, Volume: 35, Issue:23

    Topics: Anastrozole; Breast Neoplasms; Humans; Letrozole; Negative Results; Postmenopause; Receptors, Estrogen; Tamoxifen

2017
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 82

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Incidence; Letrozole; Lipids; Middle Aged; Nitriles; Propensity Score; Retrospective Studies; Tamoxifen; Triazoles

2017
Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
    Gynecologic oncology, 2017, Volume: 147, Issue:1

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Letrozole; Medical Overuse; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles

2017
Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.
    The European respiratory journal, 2017, Volume: 50, Issue:2

    Topics: Anastrozole; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Echocardiography; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hemodynamics; Humans; Hypertension, Pulmonary; Insulin Resistance; Lung; Mice; Mice, Knockout; Mutation; Nitriles; Signal Transduction; Tamoxifen; Triazoles

2017
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
    Journal of the National Cancer Institute, 2018, 02-01, Volume: 110, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Risk Factors; Tamoxifen; Triazoles

2018
Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea.
    CA: a cancer journal for clinicians, 2018, Volume: 68, Issue:1

    Topics: Amenorrhea; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Recovery of Function; Tamoxifen

2018
The Impact of Perioperative Hormonal Therapy for Breast Cancer on Transverse Rectus Abdominis Myocutaneous Flap Abdominal Complications.
    Annals of plastic surgery, 2018, Volume: 80, Issue:6S Suppl 6

    Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Incisional Hernia; Letrozole; Mammaplasty; Middle Aged; Myocutaneous Flap; Odds Ratio; Rectus Abdominis; Retrospective Studies; Risk Factors; Surgical Wound Infection; Tamoxifen; Treatment Outcome

2018
Adjuvant aromatase inhibition: more options for patients.
    The Lancet. Oncology, 2018, Volume: 19, Issue:4

    Topics: Anastrozole; Androstadienes; Aromatase; Breast Neoplasms; Humans; Letrozole; Tamoxifen

2018
Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
    Journal of the National Cancer Institute, 2017, 12-01, Volume: 109, Issue:12

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Estradiol; Female; Humans; Middle Aged; Ovarian Diseases; Ovary; Prognosis; Randomized Controlled Trials as Topic; Recovery of Function; Tamoxifen

2017
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
    Breast cancer research : BCR, 2018, 09-04, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cohort Studies; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen

2018
Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
    BMC cancer, 2018, Oct-12, Volume: 18, Issue:1

    Topics: Age of Onset; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome

2018
Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
    Clinical cardiology, 2019, Volume: 42, Issue:1

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Incidence; Medicare; Myocardial Infarction; Prognosis; Risk Factors; SEER Program; Tamoxifen; United States

2019
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019, Feb-01, Volume: 1106-1107

    Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds

2019
Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro.
    Thrombosis research, 2019, Volume: 177

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Blood Platelets; Breast Neoplasms; Cell Communication; Cell Line, Tumor; Cells, Cultured; Female; Humans; Platelet Activation; Tamoxifen; Thrombosis; Young Adult

2019
Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
    Pharmacoepidemiology and drug safety, 2019, Volume: 28, Issue:6

    Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Breast Neoplasms; Duration of Therapy; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Medication Adherence; Middle Aged; Neoplasm Staging; Practice Guidelines as Topic; Practice Patterns, Physicians'; Professional Practice Gaps; Receptor, ErbB-2; Retrospective Studies; Tamoxifen; Time Factors; Trastuzumab

2019
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:7

    Topics: Adipocytes; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Estrogens; Female; Humans; MCF-7 Cells; Obesity; Receptors, Estrogen; Stromal Cells; Tamoxifen

2019
Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
    Journal of women's health (2002), 2020, Volume: 29, Issue:1

    Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Decision Making, Shared; Female; Humans; Middle Aged; Physician-Patient Relations; Primary Health Care; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen

2020
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 02-01, Volume: 26, Issue:3

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Forkhead Box Protein M1; Gene Expression Profiling; Humans; Kruppel-Like Transcription Factors; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Securin; Survival Rate; Tamoxifen

2020
Carryover effects of aromatase inhibitors in prevention.
    Lancet (London, England), 2020, 01-11, Volume: 395, Issue:10218

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Humans; Receptors, Estrogen; Tamoxifen

2020
A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy.
    Journal of molecular medicine (Berlin, Germany), 2020, Volume: 98, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Immunotherapy; Letrozole; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Toremifene

2020
[Adjuvant radiotherapy in low-risk breast cancer: long-term results of the ABCSG-8A trial].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:7

    Topics: Anastrozole; Breast Neoplasms; Humans; Radiotherapy, Adjuvant; Tamoxifen

2020
The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
    International ophthalmology, 2020, Volume: 40, Issue:8

    Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Tamoxifen

2020
[Promising long-term results on the use of anastrozole for prevention of breast cancer in postmenopausal high-risk patients].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:10

    Topics: Anastrozole; Breast Neoplasms; Humans; Nitriles; Postmenopause; Tamoxifen

2020
Breast Cancer Risk-Reducing Medications.
    JAMA, 2020, 07-21, Volume: 324, Issue:3

    Topics: Adult; Age Factors; Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen

2020
Molecular Drivers of Onco
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 01-10, Volume: 39, Issue:2

    Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Predictive Value of Tests; Randomized Controlled Trials as Topic; Risk Assessment; RNA, Neoplasm; Tamoxifen

2021
Urinary Incontinence and Overactive Bladder Symptoms in Women with Breast Cancer Being Treated with Oral Hormone Therapy.
    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2020, Volume: 42, Issue:11

    Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Medication Adherence; Middle Aged; Portugal; Tamoxifen; Urinary Bladder, Overactive; Urinary Incontinence

2020
Switching of Hormone Therapies in Breast Cancer Women.
    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2021, Volume: 43, Issue:3

    Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Sectional Studies; Disease Progression; Female; Humans; Medical Records; Neoplasm Recurrence, Local; Patient Participation; Retrospective Studies; Tamoxifen; Young Adult

2021
Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
    BMC palliative care, 2021, Feb-05, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Anastrozole; Endometrial Neoplasms; Female; Humans; Nitriles; Palliative Care; Pilot Projects; Quality of Life; Tamoxifen; Triazoles

2021
Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report.
    Journal of medical case reports, 2021, Apr-29, Volume: 15, Issue:1

    Topics: Acromegaly; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Tamoxifen

2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genetic Testing; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Tamoxifen

2021
RE: Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients.
    Journal of the National Cancer Institute, 2022, 01-11, Volume: 114, Issue:1

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Perimenopause; Tamoxifen

2022
Design and synthesis of marine sesterterpene analogues as novel estrogen receptor α degraders for breast cancer treatment.
    European journal of medicinal chemistry, 2022, Feb-05, Volume: 229

    Topics: Anastrozole; Antineoplastic Agents; Apoptosis; Biological Products; Breast Neoplasms; Cell Proliferation; Down-Regulation; Estrogen Receptor alpha; Humans; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Protein Binding; Proteolysis; Raloxifene Hydrochloride; Reactive Oxygen Species; Sesterterpenes; Signal Transduction; Structure-Activity Relationship; Tamoxifen

2022
Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2022, Volume: 31, Issue:5

    Topics: Aged; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Humans; Letrozole; Male; Medicare; Quality of Life; Retrospective Studies; Tamoxifen; United States

2022
    Current computer-aided drug design, 2022, Volume: 18, Issue:3

    Topics: Anastrozole; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carica; Catechin; Chlorogenic Acid; Cyclophosphamide; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Ligands; Molecular Docking Simulation; Paclitaxel; Quercetin; Tamoxifen; Trastuzumab

2022
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19

    Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen

2022
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
    Clinical drug investigation, 2023, Volume: 43, Issue:3

    Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Medicare; Nitriles; Tamoxifen; United States

2023
Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-10, Volume: 41, Issue:29

    Topics: Aged; Anastrozole; Cost Savings; Drug Costs; Drugs, Generic; Humans; Imatinib Mesylate; Letrozole; Medicare Part D; Prescription Drugs; Tamoxifen; United States

2023
[De-escalation in aromatase inhibitors prescription for menopausal women with positive hormonal receptors breast cancer].
    Bulletin du cancer, 2023, Volume: 110, Issue:10

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Menopause; Tamoxifen

2023
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
    Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada, 2023, 06-09, Volume: 29, Issue:3

    Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; Mammary Neoplasms, Animal; Nitriles; Tamoxifen; Triazoles

2023
Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial.
    Cancer prevention research (Philadelphia, Pa.), 2023, 11-01, Volume: 16, Issue:11

    Topics: Anastrozole; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Patient Reported Outcome Measures; Tamoxifen

2023
Anastrozole: Repurposed drug could prevent thousands of breast cancer cases.
    BMJ (Clinical research ed.), 2023, 11-07, Volume: 383

    Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen

2023